US20210393517A1 - Body fluid expanders comprising n-substituted aminosulfonic acid buffers - Google Patents
Body fluid expanders comprising n-substituted aminosulfonic acid buffers Download PDFInfo
- Publication number
- US20210393517A1 US20210393517A1 US17/235,634 US202117235634A US2021393517A1 US 20210393517 A1 US20210393517 A1 US 20210393517A1 US 202117235634 A US202117235634 A US 202117235634A US 2021393517 A1 US2021393517 A1 US 2021393517A1
- Authority
- US
- United States
- Prior art keywords
- mmoles
- solutions
- blood
- solution
- ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001124 body fluid Anatomy 0.000 title abstract description 36
- 239000010839 body fluid Substances 0.000 title abstract description 36
- 239000000872 buffer Substances 0.000 title abstract description 14
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 title 1
- 210000003722 extracellular fluid Anatomy 0.000 claims abstract description 25
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 19
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 18
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 43
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 19
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- 229910001415 sodium ion Inorganic materials 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 229910001414 potassium ion Inorganic materials 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 abstract description 93
- 239000008280 blood Substances 0.000 abstract description 93
- 206010021137 Hypovolaemia Diseases 0.000 abstract description 22
- 206010063837 Reperfusion injury Diseases 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 16
- 230000010412 perfusion Effects 0.000 abstract description 15
- 239000008363 phosphate buffer Substances 0.000 abstract description 11
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 210000000130 stem cell Anatomy 0.000 abstract description 9
- 238000000502 dialysis Methods 0.000 abstract description 7
- 229910052816 inorganic phosphate Inorganic materials 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 239000012747 synergistic agent Substances 0.000 abstract description 6
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract description 5
- 208000033626 Renal failure acute Diseases 0.000 abstract description 5
- 201000011040 acute kidney failure Diseases 0.000 abstract description 5
- 208000012998 acute renal failure Diseases 0.000 abstract description 5
- 230000007059 acute toxicity Effects 0.000 abstract description 5
- 231100000403 acute toxicity Toxicity 0.000 abstract description 5
- 210000000683 abdominal cavity Anatomy 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 208000010444 Acidosis Diseases 0.000 abstract description 3
- 239000003124 biologic agent Substances 0.000 abstract description 3
- 230000000241 respiratory effect Effects 0.000 abstract description 3
- 206010027417 Metabolic acidosis Diseases 0.000 abstract description 2
- 208000003826 Respiratory Acidosis Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 165
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 47
- 210000000056 organ Anatomy 0.000 description 47
- 210000002966 serum Anatomy 0.000 description 47
- 241000700159 Rattus Species 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 31
- 241000282898 Sus scrofa Species 0.000 description 29
- 102000004877 Insulin Human genes 0.000 description 23
- 108090001061 Insulin Proteins 0.000 description 23
- 241000282887 Suidae Species 0.000 description 23
- 229940125396 insulin Drugs 0.000 description 23
- 210000003734 kidney Anatomy 0.000 description 22
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000012141 concentrate Substances 0.000 description 19
- 239000012530 fluid Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 17
- 235000008170 thiamine pyrophosphate Nutrition 0.000 description 17
- 239000011678 thiamine pyrophosphate Substances 0.000 description 17
- 239000000306 component Substances 0.000 description 16
- 239000011550 stock solution Substances 0.000 description 16
- 229960002363 thiamine pyrophosphate Drugs 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 239000008213 purified water Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000003860 storage Methods 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000001356 surgical procedure Methods 0.000 description 13
- 239000007992 BES buffer Substances 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 102000004420 Creatine Kinase Human genes 0.000 description 9
- 108010042126 Creatine kinase Proteins 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- -1 hydroxylethyl Chemical group 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000002980 postoperative effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 230000036387 respiratory rate Effects 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000003139 buffering effect Effects 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 238000013310 pig model Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 230000002631 hypothermal effect Effects 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 229940100601 interleukin-6 Drugs 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 229960003495 thiamine Drugs 0.000 description 6
- 235000019157 thiamine Nutrition 0.000 description 6
- 239000011721 thiamine Substances 0.000 description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 235000019743 Choline chloride Nutrition 0.000 description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000023555 blood coagulation Effects 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 5
- 229960003178 choline chloride Drugs 0.000 description 5
- 229950001485 cocarboxylase Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229960003299 ketamine Drugs 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 4
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004324 lymphatic system Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000003058 plasma substitute Substances 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003633 blood substitute Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 229960004203 carnitine Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 210000003405 ileum Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000008327 renal blood flow Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007617 Cardio-respiratory arrest Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 102000030595 Glucokinase Human genes 0.000 description 2
- 108010021582 Glucokinase Proteins 0.000 description 2
- 206010059484 Haemodilution Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195714 L-glutamate Natural products 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960001009 acetylcarnitine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000876 intercostal muscle Anatomy 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- NBIPQJXKGATNAC-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)C(O)CC(O)=O NBIPQJXKGATNAC-DKWTVANSSA-N 0.000 description 1
- DSXZIKVKQAFHAN-UHFFFAOYSA-N 1-morpholin-4-ylpropane-1-sulfonic acid Chemical compound CCC(S(O)(=O)=O)N1CCOCC1 DSXZIKVKQAFHAN-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000695608 Cisticola guinea Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- JXXCENBLGFBQJM-FYZOBXCZSA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)C[C@H](O)CC(O)=O JXXCENBLGFBQJM-FYZOBXCZSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000010455 autoregulation Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000047882 human INSR Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 230000003823 potassium efflux Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the invention relates generally to body fluid expanders.
- the invention relates to physiological liquid media for use in expanding, maintaining or replacing blood or extravascular body fluid volume. It is envisaged that the invention will find use in various medical applications, including in intravenous and extravascular (e.g. peritoneal) infusion procedures.
- Loss of blood volume also known as hypovolemia
- hypovolemia can result, for example, from a number of causes including physical injury, surgery, internal haemorrhaging or burns.
- Hypovolemia can also be induced by the intake of drugs such as diuretics and vasodilators.
- hypovolemia A significant loss of blood volume resulting from hypovolemia can be fatal unless treated rapidly. Such blood loss leads to a drop in blood pressure and a reduction in the necessary supply of blood (and with it oxygen) to essential organs and tissues. Consequently hypovolemia can result in ischemia, multiple organ failure, kidney damage, brain damage, and ultimately death.
- Hypovolemia is treated by perfusing the subject with crystalloid or colloidal fluids as a substitute for blood lost following hemorrhagic incidents. These fluid substitutes act to expand blood volume, bring about rehydration and normalise blood pressure.
- Examples of currently known blood substitutes or blood volume expanders include lactated Ringer's solution, Hartmann's solution, HES (hydroxylethyl starch) and isotonic saline (sodium chloride) (Chiara et al.; Crit Care Med. 2003; 31(7): 1915-22; Rhee et al.; J.Trauma. 1998;. 44(2): 313-319; Jernigan et al.; Am Surg. 2004; 70(12): 1094-8; Via et al.; J.Trauma. 2001; 50:1076-82).
- reperfusion injury a severe and often fatal condition known as reperfusion injury. This phenomenon is observed in subjects who have suffered from severe hypovolemia and manifests itself in the form of damage to essential organs (such as lungs, kidneys, liver, etc). The deleterious effects of reperfusion injury are usually observed between 1 to 3 days following perfusion with blood volume expanders.
- This fluid which bathes and surrounds cells, is essential to maintaining the homeostasis of tissues and organs, and functions, inter alia, as a means of delivering materials to cells, removing metabolic waste, and facilitating effective intercellular communication.
- the present invention also addresses the significant and important problem of replacement fluid treatments resulting in oedematous conditions within body organs, thereby simply augmenting the incidences of reperfusion injury.
- the invention is concerned to provide a physiological balanced fluid that complies with the composition of the interstitial fluid in all aspects, but most importantly in terms of tonicity and osmolality, and would facilitate a more natural dynamic fluid exchange between the extravascular space and interstitial phase in conjunction with the lymphatic system, thereby preventing the occurrence of oedema in surrounding tissues.
- the invention provides a non-inorganic-phosphate-buffered body fluid expander solution, that is to say a buffered body fluid expander solution in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprising calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1.
- the invention provides a body fluid expander solution, comprising a non-phosphate buffer which is selected from the group consisting of physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pK a value in aqueous solution of from 7.1 to 7.5 at 20° C., and most preferably from the group consisting of N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof
- TES N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid
- MOPS 3-(N-morpholino) propanesulfonic acid
- BES N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid
- the invention provides a body fluid expander solution, comprising calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1, and further comprising a non-phosphate buffer which is selected from the group consisting of physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pK a value in aqueous solution of from 7.1 to 7.5 at 20° C., and most preferably from the group consisting of TES, MOPS, BES and combinations thereof.
- a non-phosphate buffer which is selected from the group consisting of physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pK a value in aqueous solution of from 7.1 to 7.5 at 20° C., and most preferably from the group consisting of TES, MOPS, BES and combinations thereof.
- the non-phosphate buffer is present at a concentration of from 1 to 12 mmoles/L, preferably about 5 mmoles/L
- the body fluid expander solutions of the invention preferably comprise calcium ions and magnesium ions at a concentration ratio of from 4:1 to 2:1, more preferably about 3:1.
- the body fluid expander solutions of the invention comprise from 0.1 to 2.5 mmoles/L calcium ions and/or from 0.4 to 25 mmoles/L magnesium ions.
- the higher concentrations of magnesium ions, towards 25 mmoles/L, are useful for modifications of the solution for cardioplegic purposes, but for regular use as a body fluid expander solution the concentrations noted below are recommended.
- the body fluid expander solutions comprise calcium ions at a concentration of from 1.0 to 2.5 mmoles/L, preferably from 1.1 to 1.4 mmoles/L, more preferably from 1.2 to 1.3 mmoles/L, even more preferably about 1.25 mmoles/L.
- the body fluid expander solutions of the invention preferably comprise magnesium ions at a concentration of from 0.2 to 0.6 mmoles/L, more preferably from 0.3 to 0.5 mmoles/L, even more preferably about 0.45 mmoles/L magnesium ions.
- calcium and magnesium ions are present at a concentration of about 1.25 mmoles/L and about 0.45 mmoles/L respectively.
- the body fluid expander solutions of the invention are blood substitutes for expanding and/or replacing blood volume.
- the body fluid expanders are extravascular fluid substitutes, e.g., interstitial fluid substitutes.
- the invention also encompasses concentrated forms of the solutions defined herein.
- 1 to 50 ⁇ , preferably 5 to 20 ⁇ concentrates are encompassed.
- concentration, 5 ⁇ , 10 ⁇ , 20 ⁇ and 50 ⁇ concentrates require, respectively, 4, 9, 19 and 49 volumes of water to be added to one volume of concentrate, plus the equivalent of 2.1 g of sodium hydrogen carbonate per litre of the diluted 1 ⁇ solution.
- the invention provides solutions as defined herein for use as medicaments and blood volume expanders.
- the invention provides solutions as defined herein for use in treating hypovolemia and/or bums, and for use in preventing and/or ameliorating reperfusion injury.
- the invention provides solutions as defined herein for use in: (a) fluid replacement therapy, (b) perfusing a body cavity (e.g. the abdominal or thoracic cavity) of a subject undergoing a surgical procedure, and/or (c) intravascular or extravascular delivery of therapeutic, test and/or synergistic agents to a subject.
- a body cavity e.g. the abdominal or thoracic cavity
- c intravascular or extravascular delivery of therapeutic, test and/or synergistic agents to a subject.
- the invention also encompasses the use of a solution as defined herein for the manufacture of medicaments and blood volume expanders, e.g. for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with bums.
- the invention also provides the use of a solution as defined herein for the manufacture of a medicament for (a) treating the loss of interstitial fluid in a subject suffering with burns, (b) treating respiratory and/or metabolic acidosis in a subject, (c) perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, or (c) preventing and/or ameliorating reperfusion injury.
- the invention encompasses uses of solutions of the invention for delivering a therapeutic, test and/or synergistic agent to a subject, for example a biological agent, such as at least one stem cell, peptide or genomic derived protein.
- a biological agent such as at least one stem cell, peptide or genomic derived protein.
- the delivery is effected by administration via an intravascular, intraperitoneal, intradermal, oral, intramuscular or topical route.
- the delivery is effected by administration to the lymphatic system of a subject.
- the invention encompasses methods of treating hypovolemia and/or burns, and methods of preventing and/or ameliorating reperfusion injury, these methods comprising administering to a subject in need thereof an effective amount of a solution as defined herein.
- hypovolemia results from dehydration and/or burns and/or bleeding.
- hypovolemia is drug induced.
- the invention provides a method of maintaining physiological homeostasis of a tissue and/or organ in situ during a surgical procedure carried out on a subject, the method comprising perfusing said tissue and/or organ with a solution as defined herein.
- the solution is maintained at a temperature of between 4 and 20° C. such that said tissue and/or organ, when perfused with said solution, is maintained in a state of hypothermia.
- the surgical procedure is carried out to retrieve said tissue and/or organ from a donor subject, for subsequent transplantation to a recipient subject.
- the invention encompasses methods for delivering a therapeutic, test and/or synergistic agent to a subject using the solutions of the invention.
- the agent is a biological agent, such as at least one stem cell, peptide or genomic derived protein.
- the delivery is effected by administration via an intravascular, intraperitoneal, intradermal, oral, intramuscular or topical route.
- the delivery is effected by administration to the lymphatic system of a subject.
- the invention provides the use of a solution as defined herein for (a) dialysis of the peritoneal cavity in a subject suffering from acute renal failure or an acute toxicity condition; and/or (b) irrigation of abdominal and/or thoracic organs in a subject undergoing a surgical procedure.
- the invention encompasses a substantially inorganic-phosphate-free buffered solution for use as a medicament, especially one that is also substantially free of at least one of citrate and lactate buffer
- FIG. 1 Assessment of the survival of rats over time as a function of the resuscitation solution used. Rats were subjected to serial withdrawals of blood. The rats were separated into three experimental treatment groupings as follows: (1) replacement of blood with physiological saline; (2) replacement of blood with a preferred solution in accordance with the invention, referred to herein as RS-I solution or RS-I; and (3) no replacement of blood losses. Survival of rats in each of the various groupings was monitored and the data set out in FIG. 1 .
- FIG. 2 Comparison of the total volume of blood withdrawn for each of the study arms defined with reference to FIG. 1 above. Blood was withdrawn from rats as described in the Example 4 below.
- FIG. 3 Assessment of the respiratory rates of rats over time in the various study arms defined with reference to FIG. 1 .
- FIGS. 4A, 4B, 4C, 4D, 4E and 4F Assessment of pig blood profiles over various time periods of perfusion with RS-I. Pigs were infused with 1.0 L of RS-I solution every day for three days and blood samples were taken at various time points.
- Blood samples were tested, inter alia, for complete blood counts, serum chemistry determination, electrolytes, glucose, lactate, osmolality, serum enzymes (serum glutamic oxaloacetic transaminase/aspartate aminotransferase [SGOT/AST], serum glutamic pyruvic transaminase/alanine aminotransferase [SGPT/ALT], creatine kinase [CK] and lactate dehydrogenase [LDH]), coagulation factors and fibrinogen levels. Also, blood was measured for interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- ⁇ ).
- IL-6 interleukin-6
- TNF- ⁇ tumor necrosis factor-alpha
- FIG. 4G Summary Data Table re Blood Data Analysis in a Normovolemic Pig model.
- FIGS. 5A, 5B,5C, 5D, 5E, 5F and 5G Analysis of Serum Electrolyte Levels in a Normovolemic Pig model
- FIGS. 6A, 6B, 6C and 6D Analysis of Serum Metabolites Levels in a Normovolemic Pig model
- FIGS. 7A, 7B, 7C and 7D Analysis of Serum Enzyme Levels in the a Normovolemic Pig model
- FIGS. 8A, 8B, 8C, 6D and 6E Analysis of Blood Cell Profiles in a Normovolemic Pig model
- FIGS. 9A, 9B, 9C and 9D Analysis of Blood Clotting Parameters in a Normovolemic Pig model
- FIG. 10 Comparison of the ADP:ATP (adenosine diphosphate: adenosine triphosphate) ratios in cold static (CS) and warm static (WS) group pig kidneys before and after 6 hours of normothermic perfusion.
- ADP:ATP adenosine diphosphate: adenosine triphosphate
- FIG. 11 Change in the mean Arterial Pressure following resuscitation in Autologous Blood, RS-I fluid and Lactated Ringer's saline
- FIG. 12 Activated Prothromboplastin Time (aPTT) following resuscitation in Autologous Blood, RS-I fluid and Lactated Ringer's saline
- FIG. 13 Activated Partial Thromboplastin Time (aPTT) during Experimental Period
- body fluid expander or “body fluid expander solution” or “body fluid substitute” as used herein mean a physiological liquid solution which is intended for use in replacing or expanding body fluid, and/or maintaining a sufficient volume of body fluid.
- body fluids for which the solutions of the invention are intended to expand, replace or maintain include intravascular fluids (e.g. blood components such as plasma), or alternatively, extravascular fluids (e.g. interstitial fluid).
- body fluid expander and “body fluid expander solutions” also encompass physiological liquid media which are intended for use as a vehicle for the delivery of therapeutic, test and/or synergistic agents into the body of a subject in need of said agents, or in circumstances where the agents are to be tested, for example on non-human subjects.
- subject or “subjects” encompasses, where appropriate, human subjects and non-human animal subjects, for example mammalian subjects such as rodents, pigs, monkeys, dogs and the like as appropriate in experimental research and cattle, horses and the like as occurs in veterinary practice.
- non-phosphate buffer and “substantially phosphate free” are intended to encompass fluid embodiments which substantially lack inorganic phosphate ions.
- blood volume expander or “blood volume expander solution” or “blood substitute” as used herein mean a physiological liquid solution which is intended for use in replacing, expanding or maintaining blood volume. These solutions therefore find use in substituting for a loss of blood volume resulting from hypovolemia.
- hypovolemia means a state of decreased blood volume, or more specifically, a state of decreased blood plasma volume.
- Common causes of hypovolemia include dehydration, burns, bleeding (e.g. haemorrhaging) or the intake of certain drugs such as diuretics and vasodilators.
- reperfusion injury means the injury caused to essential organs of the body following hypovolemia and subsequent perfusion with conventional blood volume expanders.
- the present invention emerges from a realisation of the inventor that conventional blood volume expanders are detrimental to the maintenance of cell, tissue and organ survival and viability, and can hence contribute to the development of reperfusion injury.
- the present invention stems from an appreciation that the composition of blood volume expanders (and physiological media in general) should be based on a specific knowledge of the activity coefficients of ionic species within the interstitial gel phase surrounding each cell. These activity coefficients have been calculated and the solutions of the present invention have been designed in accordance with these calculations.
- the solutions of the invention make use of non-phosphate buffers, based on the realization that excess phosphate ions can be deleterious to the viability and functional integrity of perfused cells, tissues and organs.
- Phosphate ions inhibit glycolysis, oxidative phosphorylation (Berman & Sanders; Circul.Res., 1955; 3, 559-563), creatine kinase activity (Hall & DeLuca; Adv. Exp. Med. Biol. 1986; 194, 71-82) and the enzymes involved in oxygen free radical scavenging (De Frietas & Valentine; Biochemistry 1984; 23:2079). These enzymes are important in inducing apoptotic changes at the cellular level, ultimately leading to the necrosis (i.e. death) of damaged or abnormal cells, tissues and organ systems.
- non-phosphate buffered solutions avoids the inefficiency of conventional phosphate buffered solutions in terms of instability above pH 7.2.
- inorganic phosphate ions in conventional solutions are, over time, precipitated in the form of insoluble calcium phosphate (Pedersen, MD Thesis, University of Arhus, Denmark. Publ. S A Moller Christensen A/S. 1973; 41-51). This problem is accentuated by variations in the temperature range at which the solutions are used and therefore such conventional buffered solutions are of limited clinical utility.
- non-phosphate buffer agents e.g., citrates, certain amino acid combinations, and lactated solutions
- citrates e.g., certain amino acid combinations, and lactated solutions
- the solution of the invention when in use as a body fluid expander, has enhanced performance because it is capable of utilising the natural buffer system found in all mammals, namely, a pCO 2 /hydrogen carbonate system.
- body fluid expander solutions which, by virtue of their composition, are able to compensate either for loss of blood in hypovolemic subjects, or loss of interstitial and extracellular fluid associated with severe burns.
- the body fluid expander solutions of the invention provide physiological liquid media which mimic the ionic, substrate and biophysical environment of interstitial fluid (see, for example, Table II below). As such, it is envisaged that these solutions will find use as universal perfusion and preservation media.
- concentrations of ion species acknowledge the activity coefficients of each ionic species within the interstitial gel phase around mammalian cells. This is in contrast to many conventional media which base their concentrations on total serum concentrations.
- the body fluid expander solutions of the present invention are preferably free of serum and/or serum components.
- the solutions are hence free of animal derived serum proteins and other contaminants, such that there are no undefined, extraneous serum proteins present.
- the absence of serum has the advantage that the solutions are “chemically” better defined than conventional serum based solutions.
- the absence of serum and serum derived components avoids concerns over the possible transmission of infectious diseases (e.g. Human immunodeficiency virus (HIV) and Creutzfeldt-Jakob disease (CJD) associated with the use of this material in vivo.
- infectious diseases e.g. Human immunodeficiency virus (HIV) and Creutzfeldt-Jakob disease (CJD) associated with the use of this material in vivo.
- the body fluid expander solutions of the present invention are also preferably free of foreign or animal derived antigens, pyrogens, proteins and the like.
- susceptible patients may require the presence of specific peptide or protein derived components as a compensatory measure for the reported loss of proteins during renal or peritoneal dialysis.
- the solutions of the invention may provide effective vehicles for use in delivering such components to patients.
- a major discovery that has evolved during work with solutions similar to the solutions of the present invention in isolated tissue and organ perfusion experiments is that they can utilise the natural pH buffering mechanisms observed in all mammalian species, namely, auto-regulation of the partial pressure of carbon dioxide [pCO 2 ] and concentration of the bicarbonate ion [HCO 3 ] in blood even in the absence of red blood cells.
- the interrelated dissociation constant [pK a ] afforded by the imidazole/histidine moieties of hemoglobin appears to be simulated by suitable buffers used in this invention, most preferably BES buffer which, because of its useful pK a (7.15) and ⁇ pK/° C.
- the body fluid expanders of the present invention adopt and take advantage of a natural physiological buffering system.
- this buffering system takes the form of NaHCO 3 /pCO 2 (sodium hydrogen carbonate/dissolved CO 2 ) in combination with the zwitterionic Good's buffer, BES (N, N-bis [2-Hydroxyethyl]-2-amino-ethanesulphonic acid (Good et al.; Biochemistry 1966; 5:467-477), incorporated herein by reference), which acts by virtue of its ideal pK a over a temperature range of 10 to 37° C., to provide a stable pH, an essential requisite for cellular preservation.
- BES zwitterionic Good's buffer
- BES has been shown to be non-toxic to cultured mammalian cells in long term studies and exhibits negligible binding of calcium or magnesium ions, so removing the potential hazard of precipitation of divalent ions which occurs when using conventional hydrogen carbonate/phosphate or double phosphate buffer solutions. Indeed, 10 ⁇ concentrates of solutions according to the invention have been experimentally shown to have a shelf life (stored at 3 to 8° C.) in excess of 14 months.
- MOPS morpholinopropane sulphonic acid
- TES N-tris-(hydroxymethyl) methyl-2-amino ethane-sulphonic acid
- N-substituted aminosulfonic acid buffers may be chosen according to specific requirements, and the following Table lists potential candidates and their pK a values in aqueous solution at 20° C.
- the non-phosphate buffer (preferably TES, MOPS or BES, or combinations thereof) is present at a concentration of from 1 to 12 mmoles/L, preferably from 3 to 7 mmoles/L, more preferably from 4 to 6 mmoles/L, even more preferably about 5 mmoles/L.
- hydrogen carbonate ions are present at a concentration of from 21 to 35 mmoles/L, preferably from 23 to 26 mmoles/L, more preferably about 25 mmoles/L.
- the non-phosphate buffer systems used allow, because of their unique pK a range, the ability to automatically adjust the pH of the solutions of the invention from 7.05 to 7.5 over a temperature range of from 4° C. to 38° C.
- This feature of the invention unlike that found with conventional buffering systems, does not require any further intervention in adjusting the pH to give values ranging from 7.13 to 7.5 ⁇ 0.5 over a temperature range of 10 to 38° C.
- the solutions of the invention have a pH of about 7.46 at a temperature of about 37.4° C. It is preferred that the above pH values are maintained in vivo following administration of the solutions to a subject in need thereof.
- the solutions of the invention may be used for both intra- and extravascular infusion procedures.
- the solutions may also be used to perfuse isolated animal and human organs under normothermic conditions.
- carbogen gas 95% oxygen/5% carbon dioxide.
- the body fluid expander solutions of the present invention may also comprise in any combination, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, or all of the following components: from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) ⁇ moles/L glycerol, from 7 to 15 (preferably about 10) ⁇ moles/L choline, from 5
- Chloride ions when present, are preferably provided as sodium, potassium, calcium and magnesium salts.
- choline is provided as a chloride salt.
- Solutions encompassed by the present invention comprise a number of substrates which retain metabolic homeostasis of tissues and organs.
- Glucose and glycerol have been shown to be satisfactory in meeting the energy demands of isolated tissues and organs, even when they are not the preferred substrate for the organ in question (e.g. the heart) by the inclusion of physiological levels of insulin.
- glycerol and glucose Apart from their ability to be metabolized, glycerol and glucose also have free radical scavenging and membrane stabilizing properties, which have been shown to be extremely important in maintaining the physiological viability of tissues and organs.
- aspartate and glutamate can also be included in the solutions according to the invention, to enhance oxidative metabolism by replenishing tricarboxylic acid (TCA) cycle intermediates, thereby maintaining high energy phosphate levels even during ischemic insult.
- TCA tricarboxylic acid
- glutamate is involved in maintaining intracellular oxidation-reduction potentials. It is envisaged that by optimizing the aspartate-malate and glycerol phosphate shuttles, cells will maintain an optimal NAD/NADH (nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide) balance and thereby sustain adenine nucleotide levels.
- NAD/NADH nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide
- glutamate and glutamine can act as intermediary metabolites to form pyroglutamate and thereafter participate in the gamma-glutamyl cycle to synthesise glutathione, a beneficial agent in preventing the generation of toxic oxygen radicals associated with the incidence of reperfusion injury in mammalian tissues and organs during storage of donor organs prior to transplantation and following blood volume replacement therapies.
- Thiamine plays an important role in the oxidation of ⁇ -keto acids (by the action of thiamine cocarboxylase) and prevents the accumulation of pyruvate and toxic pyruvate aldehyde, thereby minimizing cellular apoptosis and accompanying necrosis of tissues and associated organs.
- thiamine pyrophosphate which is included in preferred solutions of the invention, is a co-factor in the metabolism of a-ketoglutaric acid to form succinyl-coenzyme A, by oxidative decarboxylation, or to form glutamate, by reductive amination.
- TPP is involved in numerous interrelated biochemical pathways, especially those of the Pentose Phosphate and Glycolytic pathways.
- the thiamine may be employed as thiamine pyrophosphate, thiamine diphosphate or thiamine diamide.
- the solutions of the invention comprise thiamine as thiamine pyrophosphate chloride.
- thiamine pyrophosphate in the formulation of the solutions of the invention would also appear to be of necessity to peritoneal dialysis patients in order to prevent phosphate ion depletion and calcification as it is readily dialyzable across hemodialysis membranes (MW—175 Dalton) and has been previously administered either intravenously or via the hemodialysis or peritoneal dialysis solution to replenish plasma phosphate and/or pyrophosphate levels.
- the vitaminoid carnitine has been reported to have multiple effects in improving cardiac function other than by simply optimizing oxidative metabolism, such as, by promoting the utilization of alternative substrates and may additionally improve coronary blood flow.
- L-carnitine is preferred to the D- or DL isomers because it causes no inhibition of acetyl co-enzyme A/free fatty acid metabolism.
- the vitaminoid component comprises 50 ⁇ moles/L of [-]- ⁇ -hydroxy- ⁇ -trimethylamino-butyrate hydrochloride (L-carnitine).
- the preferred inclusion of the L-isomer of carnitine is intended to optimise the transport of long chain fatty acids from the cytosol into the mitochondrial matrix to the site of 13-oxidation and thereby to buffer the intramitochondrial acetyl CoA/CoA ratio (where CoA is Coenzyme A) by stimulating the synthesis of acetyl carnitine from carnitine acetyl transferase.
- This reduction in the ratio of acetyl CoA/CoA will result in an efflux of acetyl carnitine from the mitochondria with an associated stimulation of pyruvate dehydrogenase and reversal of fatty acid inhibition of glucose oxidation.
- solutions of the invention may also comprise insulin.
- human recombinant insulin e.g. expressed in E. coli or S. cerevisiae
- insulin molecules may be the case with insulin derived from other mammalian or animal sources, but also leads to a better fit being achieved of insulin molecules to human insulin receptor structure, i.e. Receptor specificity will be optimized to retain the many associated functions of insulin in cellular processes.
- the biological effects of insulin do not simply relate to its ability to regulate carbohydrate metabolism and facilitated transport of circulating glucose into cells but also in its ability to bring about (i) the enhancement of intracellular glucokinase activity and amino-acid incorporation into protein, (ii) stimulation of DNA (deoxyribose nucleic acid) translation into proteins, (iii) increased lipid synthesis and (iv) stimulation of sodium, potassium and inorganic phosphate transport across cell membranes.
- normal, human serum levels of insulin have been utilized.
- conventional known perfusate formulations have, when incorporating insulin, made use of unnatural levels of this hormone (e.g. 10 to 50 ⁇ 10 6 mIU/L; about a million times more concentrated that the insulin found in solutions of the invention).
- the reason for this relates to the fact that only a small amount of the insulin exists as single molecules in such concentrations.
- the rest of the insulin exists in the form of large aggregates, which are ineffective at stimulating insulin receptors and are hence biologically inactive.
- the solutions of the invention achieve normal, human serum levels of insulin by acidifying the insulin during formulation to prevent aggregate formation, so allowing individual active, molecular species of insulin to exist in solution at pH 7.3 ⁇ 0.2.
- the concentrations of ionic species in solution according to the invention acknowledge the activity coefficients of each ionic species and not simply their total serum concentrations.
- serum binding of calcium and magnesium ions must be distinguished from the actual free, ionized levels of these ions.
- Magnesium ions are important in a number of critical cellular reactions and their extracellular presence is reported to stimulate mitochondrial respiratory activity and modulate the effects of rapid calcium influx and potassium efflux. Equally, an adequate concentration of calcium ions is important to maintain the free levels of this ion present in the circulation.
- the ionic conductivity of the solutions of the invention is preferably comparable to that of human serum, namely 12.0 ⁇ 0.3 mS cm ⁇ 1 and as such maintains the ionized status of the cell membrane and activities of enzymic moieties.
- the solutions of the present invention are isosmotic to human serum (ca. 290 mOsmoles/L) and do not appear to necessitate the inclusion of plasma expanders, as demonstrated by the fact that only minor changes (ca. 8%) in hydration occur during long term (i.e. 4 to 52 hr) hypothermic perfusion of the isolated rat heart and visceral nerve-muscle preparations. This may be explained by the fact that the cell membrane lies in continuity with a 99% gel interstitial phase so providing natural colloidal buffering to excess Donnan ionic equilibrium exchange across the cell membrane. The majority of the osmotic pressure is provided by sodium ions and their accompanying anions, and only a small component (ca.
- colloidal expanders are essentially non-toxic, their use is contraindicated in terms of, for example, (1) raised viscosity increases the thickness of the ‘unstirred’ layer around cells so hindering diffusion of metabolites, (2) alteration of the surface membrane bioelectric potential so disrupting cellular metabolism and receptor activities, (3) antigenicity of proteinaceous expanders, (4) agglutination and haemolysis of red blood cells (RBC's) and (5) blockage of microvasculature and ischemia.
- RBC's red blood cells
- the solutions of the invention will find general use as base compositions to which additional components can be added, depending upon the specific medical purpose.
- the solutions of the invention could be supplemented with, for example, red blood cells (RBC's), plasma and/or platelets for the generation of artificial blood.
- RBC's red blood cells
- plasma plasma and/or platelets for the generation of artificial blood.
- blood components may be either natural or artificial.
- additional chemicals can be added to the base composition as and where required.
- the solutions of the invention find use in methods for treating hypovolemia or the loss of interstitial and extracellular fluid brought about in subjects suffering from severe burns.
- the solutions of the invention are applicable in methods of preventing and/or ameliorating reperfusion injury.
- the solutions of the invention therefore find use as medicaments.
- the patient will be placed securely in a recumbent position and clinically prepared for the intravenal administration of the specific medicament adopting conventional, clinical procedures. Delivery of the said medicament to the patient will be executed under controlled, supervised conditions until completion of the treatment is achieved.
- the solutions of the inventions will also find other uses which include the following; for maintaining, preserving and irrigating tissues and organs in situ during surgical procedures, for perfusing the abdominal cavity of a subject suffering with an acute renal failure or an acute toxicity condition, and for preserving donor tissues and organs in situ during surgical procedures for their removal from the donor patient.
- the solutions of the invention may also be administered by other routes, for example, using intraperitoneal, intradermal, intramuscular, topical or oral routes.
- the patient will be prepared under anesthesia for surgical intervention whereby cannulae will be inserted into the peritoneal cavity, secured in position to ensure the continuous irrigation with the solution under normothermic temperatures. Removal of the peritoneal cannulae will be performed under surgical conditions once normalcy has been achieved in the patient's blood chemistry analysis.
- the methods, solutions and medicaments of the invention are for use in treating human and non-human mammalian subjects, e.g., humans.
- one application of the solutions defined herein is for preserving donor organs in situ before, during and after surgical procedures for their removal from the donor subject.
- Use of the solutions of the invention in this regard could involve, for example, whole body infusion (Extra Corporeal Membrane Oxygenation [ECMO] procedure) with donor kidneys, heart, liver, etc being harvested from a donor cadaver followed by normothermic reperfusion of the isolated organ.
- ECMO Extra Corporeal Membrane Oxygenation
- RS-I as defined herein (see Examples) has the ability to re-animate hypothermically preserved cadaver human organs allowing such organs to be used in preclinical drug bioassay trials, thereby addressing the problem of Adverse Drug Reactions (ADR) reported to occur using in vitro and in vivo drug assessment in animal models.
- ADR Adverse Drug Reactions
- the solutions of the invention will find use as media for the effective delivery of agents to a subject in need thereof, or in circumstances where the agents are to be tested, for example on non-human subjects.
- the solutions of the invention may find use as diluents for the delivery of pharmaceutical, test or synergistic agents or, alternatively, for the delivery of stem cells, peptide or genomic derived protein. to a subject in need thereof
- the delivery of stem cells could, for example, be brought about by suspending the stem cells in media as defined herein, and delivering the resulting suspension directly to the tissue or organ where required.
- stem cell types e.g., cardiomyocytes, hepatocytes
- Further proliferation of the stem cell type will be conducted using current culture media techniques whereafter the cells will be re-suspended in the solution and transported to the patient's bedside under hypothermic or mild hypothermic conditions prior to execution of the therapy.
- Patients will undergo local or general anesthesia dependant upon the route of administration of the stem cell-derived therapy, e.g., local anesthesia for intramyocardium administration of cardiomyocytes, and the administration of the therapy conducted at normothermic temperatures under good clinical practice.
- delivery may be effected by administration of the suspension to the lymphatic system.
- the invention envisages that specific sub-components of the solutions of the invention can be used individually or in any combination.
- Thiamine pyrophosphate (cocarboxylase), Sigma C4655 was prepared as a 0.4 mg/mL stock solution in purified water and stored frozen in dark glass vials.
- Choline chloride (Sigma C7527) was prepared as a 17.5 mg/mL stock solution in purified water and stored frozen in glass vials.
- Human recombinant insulin (Sigma 10259/12643) was prepared as a 0.5 I.U./mL stock solution in purified water acidified to pH 2.4 with 0.12N hydrochloric acid and stored frozen in glass vials.
- the 10 ⁇ RS-I solution was sterile filtered through a Sartobran PH 2 O cartridge/0.2 micrometer filter (Sartorius Corp. USA) into 100 mL sterile sealed glass bottles.
- This RS-I solution is a 10 times concentrate of the solution intended for use, but with sodium hydrogen carbonate withheld. When needed, the 10 ⁇ RS-I solution can be diluted with the appropriate quantity of purified water, and sodium hydrogen carbonate added.
- concentrate RS-I solution For preparation of the 1 ⁇ RS-I solution, 100 ml of the above 10 times concentrate RS-I solution may be diluted with 900 mL of purified water to 1 litre with the addition of 2.1 g of endotoxin-free sodium hydrogen carbonate (Sigma S4019) and stored at 8-10° C. prior to use.
- Sodium hydrogen carbonate is preferably not added to the concentrate solutions before they are stored, since extended storage of the concentrate containing hydrogen carbonate ions may cause precipitations of calcium carbonate.
- Stock 1 ⁇ solutions for short-term storage may contain sodium hydrogen carbonate.
- each litre of the solution may contain 100 mg/L of chloramphenicol (Sigma C3175) or other conventional antibiotics or antifungal agents to prevent the risk of bacterial infection.
- chloramphenicol Sigma C3175
- other conventional antibiotics or antifungal agents to prevent the risk of bacterial infection.
- irradiation of the solution to achieve sterility will result in degradation of glutamine, glucose, insulin and thiamine pyrophosphate components; 4) The use of glass bottles for storage of all 10 times stock concentrate solutions; 5) Preparation of solubilised insulin by acidification at pH 2.4 plus storing insulin ingredients and stock solutions at ⁇ 20° C.; 6) Preparation of thiamine pyrophosphate plus TPP stock solutions stored at ⁇ 20° C. under dark conditions (see reason below); 7) Preparation of Choline chloride stock solutions stored at ⁇ 20° C.; 8) Use of magnesium chloride hexahydrate (i.e. 6H 2 O).
- Stock solutions Various stock concentrations of solutions according to the invention namely, 1 ⁇ , 10 ⁇ and 20 ⁇ for long-term storage have been prepared, but the preferred stock concentrates are 10 ⁇ concentrates using purified water sterile filtered into sealed 100 mL bottles for storage under dark conditions at 3 to 8° C. Stock solutions are reconstituted for use as 1 ⁇ solutions by the addition of 100 mL of 10 ⁇ concentrates of stock solutions to 900 mL of purified water with the addition of 2.1 g of sodium hydrogen carbonate to give a final pH of 7.22. ⁇ 0.04 at 20° C. Sterile stock 10 ⁇ concentrations of solutions according to the invention have a pH of 4.6. ⁇ 0.2 and have been shown to remain sterile, and free of precipitations, for periods of up to ten years.
- Cocarboxylase Stock solutions of thiamine pyrophosphate chloride (cocarboxylase) are prepared at 18.4 g/mL using endotoxin-free purified water, sterile filtered into dark sealed vials to prevent the photon degradation of thiamine pyrophosphate, and stored frozen prior to the assemblage of 10 ⁇ stock concentrates of solutions according to the invention.
- Insulin Human recombinant insulin is prepared as acidified (pH 2.4) stock concentrated solutions at 0.5 m I.U./mL using endotoxin-free purified water and sterile filtered into sealed vials and stored frozen prior to the assemblage of stock concentrates of solutions according to the invention. 4.
- Choline Stock solutions of choline chloride are prepared at 17.45 mg/mL using endotoxin-free purified water and stored frozen in sealed vials prior to the assemblage of stock concentrates of solutions according to the invention. 5.
- Chloramphenicol is not an essential component of solutions according to the invention but is preferably added, either for storage, or after the storage vials have been opened, to ensure sterility during extended exposure of the solutions to the atmosphere and to lower the risk of infection to subjects treated with the body fluid expander solutions of the invention.
- RS-I represents a preferred form of the body fluid expander solution in accordance with the invention.
- EXAMPLE 3 A Comparison of the Chemical Constituents of RS-I, Human Serum and Human Interstitial Fluid
- This Example sets out a comparison of the various levels of components present in human serum, human interstitial fluid and RS-I solution, as given below in Table II.
- the procedures consisted of a lower midline laparotomy under sterile conditions after induction of full anesthesia using an intramuscular (IM) injection of 0.1 cc Xylocaine +0.2 cc ketamine for every 100 gram body weight. Following this, the aorta of the rat is dissected and cannulated under direct vision using a 24 Gauge angiocath. This allows for direct access for large amounts of blood withdrawal as well as administration of solutions. As a maintenance dose, 0.2 cc IM injections of ketamine are given every 25 minutes to all rats. Animals are allowed to breathe spontaneously throughout the experiment and their respiratory rate is continuously monitored. A warmer is used to keep the rats at normal body temperature during experimentation.
- IM intramuscular
- the bowels become exposed to unveil the abdominal vessels.
- the bowels are wrapped with wet gauze (soaked in saline) to minimize water loss.
- the rat is either sacrificed while under anesthesia or the aortic perforation at the site of the catheter is repaired using 6-0 Prolene figure of 8 sutures and closure of the laparotomy incision using 2-0 Vicryl suture in 2 layers.
- the rats chosen for the survival part of the study are given intramuscular antibiotics and allowed ad lib feeding post-operatively. This procedure takes 25 to 30 minutes to complete per rat.
- the rats were subjected to serial withdrawals of blood in 2cc increments (simulating controlled hemorrhage) every 30 minutes. At the end of each withdrawal a 0.1 ml of heparinized solution (1000 units in 20 ml of normal saline) was injected into a heparin lock to avoid blood clotting. The rats were randomly allocated to one of 3 arms as defined above.
- FIG. 1 The survival of rats over time as a function of the resuscitation solution used is illustrated in FIG. 1 . Rats in the ‘no’ resuscitation arm had the shortest survival. Survival time was significantly improved by adding either saline replacement of blood losses or RS-I replacement. Both solutions showed a significant difference when compared with the survival time of non-resuscitated rats; the mean difference between RS-I and ‘no’ resuscitation groups was 89 ⁇ 13.13 minutes (p ⁇ 0.01), and between saline and ‘no’ resuscitation was 57 ⁇ 15.87 minutes (p ⁇ 0.05). RS-I was superior to saline and resulted in a statistically significant increase in the survival time. The mean difference in survival times between the RS-I treated rats and saline treated rats was significant at 43.40 ⁇ 6.90 minutes (p ⁇ 0.01).
- Blood volume withdrawn The total volume of blood withdrawn for each of the study arms is set out in FIG. 2 . Both groups of fluid resuscitated rats showed a significant difference in the volume of blood withdrawn compared to the control arm of ‘no’ resuscitation (RS-I to ‘no’ resuscitation 5.73 ⁇ 0.62 ml and saline to ‘no’ resuscitation 3.64 ⁇ 0.70 ml, with p ⁇ 0.01 for both). The mean difference in volume of blood withdrawn from RS-I resuscitated rats in comparison to saline resuscitated rats was found to be statistically significant (p ⁇ 0.01) at 2.82 ⁇ 0.45 ml.
- FIG. 3 illustrates the respiratory rates of rats over time in the various study arms.
- RS-I resuscitated rats survived the greatest time and showed a slower decline in the respiratory rate overall, though initially (first 100 minutes) a more rapid descent in respiratory rate was noted.
- the overall respiratory rate for saline resuscitated rats declined at a rate faster than that of RS-I infused rats and this decline was even faster still for the rats that received no fluid infusion.
- RS-I appears to be a more effective plasma substitute than physiological saline with respect to survival time and volume blood loss in a rat model of controlled hemorrhagic shock.
- This study was designed as a pilot study to evaluate the safety of RS-I when administered as an intravenous (IV) infusional agent in a large animal model (swine).
- IV intravenous
- pigs were used in this study arm, of both genders, ranging in weight from 27 to 35 kg.
- the pigs were housed in the animal care facility and were kept NPO (nothing by mouth) overnight on the night prior to the study.
- NPO nothing by mouth
- Each pig was housed in a separate cage.
- each pig was initially sedated using an intramuscular injection of ketamine (15 to 20 mg/kg) followed by induction of anesthesia and endometrial intubation. Anesthesia was maintained with halothane to achieve absence of response to surgical stimulation without depression of heart rate. Each pig received pre-operative antibiotic prophylaxis by intramuscular injection of gentamycin 10% (1 cc/10kg).
- a central venous catheter was surgically placed via direct countdown, under strict aseptic conditions, into the left internal jugular vein of each pig.
- the central line was extensively tunneled in the subcutaneous tissues of the pig to an exit site on the lateral and dorsal aspect of the pig neck and secured in place. This was done for two purposes; to prevent accidental catheter dislodgement and to minimize the risk of line related infections.
- the animals were then allowed to return to their cages to recover from the anesthetics.
- each pig was sedated using intramuscular injection of ketamine (35 mg/kg) and xylazine (7 mg/kg).
- Baseline blood samples were drawn from the central line under aseptic technique and immediately sent to the lab for analysis.
- the blood profile drawn was tested for complete blood counts, serum chemistry determination: electrolytes, osmolality, pH, glucose, lactate, creatinine, blood urea nitrogen (BUN) , serum enzymes (aspartate aminotransferase [SGOT/AST], alanine aminotransferase [SGPT/ALT], total creatine kinase [CK] and lactate dehydrogenase [LDH]), coagulation factors and fibrinogen levels.
- blood was taken for measurement of pro-inflammatory activity, e.g., neutrophil activation, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a), and the samples centrifuged and stored at ⁇ 80° C. for later evaluation.
- pro-inflammatory activity e.g., neutrophil activation, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a)
- IL-6 interleukin-6
- TNF-a tumor necrosis factor-alpha
- each pig had 1.0 L of RS-I (at room temp) infused slowly over 1-2 hours via the central line.
- the pig was directly monitored during the infusion for any signs of ill health or unusual behaviour/manifestations.
- the pigs were then allowed to return to their normal living quarters and were monitored by the animal house veterinarian for any signs of ill health or unusual behavior/manifestations.
- RS-I the same blood profile (described below) was drawn to evaluate for any ill effects related to the RS-I administration.
- the pigs were then monitored for 7 days and euthanized humanely on Day 7 by intravenous potassium chloride solution administration under sedation with ketamine. Prior to euthanasia, a final blood sample (Day 7) was collected. Blood samples were also drawn to measure TNF- ⁇ and IL-6. These samples were centrifuged at 2000 r.p.m. [20° C.] for 5 minutes and then stored at ⁇ 80° C. to be later processed using commercially available porcine ELISA assays.
- a post-mortem examination was performed on every pig, and organs (brain, lungs, liver and kidneys) were harvested and either stored in formaldehyde or frozen at ⁇ 80° C. for histological examination and apoptotic testing at a later date.
- Each normovolemic pig had an estimated total blood volume of 1.8-2.3L (67 mL/kg) and each pig received a total volume of 3L of RS-I over a period of 72 hours.
- No hemodilution of RBC count was observed with hematocrit (Hct) values and hemoglobin (Hg) levels remaining with normal ranges up to Day 7 ( FIG. 8 a,b,c ).
- volume replacement therapies are susceptible to the incidence of inflammatory, anaphylactic, hypercoagulability episodes, seemingly related to the antigenicity and/or toxicity of the various excipients used in the formulation of the blood replacement fluids administered. This does not appear to be the case in the intravenous administration of RS-I solution from the analysis of the blood cell profile data obtained.
- LDH Lactate Dehydrogenase
- EXAMPLE 6 A Study of Isolated Kidney Function Following Preservation using RS-I
- Non-heart beating donor (NHBD) pig kidneys were preserved for 2 hours under ‘cold’ (0° C. to 4° C.) static (CS) conditions in either RS-I or the commercial hypothermic preservation solutions, Soltran or UW (University of Wisconsin) or for 2 hours under ‘warm’ (31° C.) static (WS) conditions.
- the kidneys were subsequently reperfused with a 50:50 autologous blood/Lactated Ringer's perfusate mixture under normothermic conditions for periods of 6 to 8 hours.
- RS-I significantly outperformed other preservation solutions in maintaining renal function as assessed following kidney re-animation in autologous blood.
- Analyses of the data obtained over the reperfusion periods revealed that kidneys preserved in RS-I at 4° C. exhibited (1) increased oxygen consumption, (2) increased creatine clearance rates, (3) increased renal blood flow [RBF], (4) increased urine output, (5) decreased renal vascular resistance [RVR], (6) deceased weight gain (i.e. less oedema), (7) stable blood pH and retention of acid-based balance [bicarbonate ion levels], and (8) negligible loss of intracellular K + .
- EXAMPLE 7 Assessing the Capability of RS-I to Maintain Isolated Mammalian Organ and Tissue Preparation Viability over Various Time Periods of Preservation
- Functional viability of mammalian tissue and organ preparations was assessed following storage/perfusion of the tissues/organs for various periods in RS-I solution. Viability was assessed using a variety of functional indicators, e.g., maintenance of cell membrane potentials, neurotransmitter output, myogenicity, membrane receptor sensitivity, enzyme functions, histological changes, etc.
- Table IV below reveals the ability of RS-I solution to maintain functional viability of various mammalian animal and human tissues and organs preparations over preservation periods of varying length (between 0.3 to 10 days).
- EXAMPLE 8 A Preclinical Study to Compare the Efficacy of RS-I Fluid with Autologous Blood and Saline Solution when Administered Intravenously in a Hemorrhagic Pig Model
- the resuscitation fluids were given in a dynamic manner, incrementally, over a 2-hour period to maintain the MAP at 60 +/ ⁇ 2 mm Hg. All hemodynamic parameters were measured at baseline; at initiation of the 45- minute shock period, at 30 minutes of shock; at 45 minutes (completion) of shock; and at 30, 60, 90, and 120 minutes of resuscitation.
- serum enzymes aspartate aminotransferase [SGOT/AST], alanine aminotransferase [SGPT/ALT], total creatine kinase [CK] and lactate dehydrogenase [LDH]
- the animals After resuscitation, the animals had their cannulae removed leaving the neck venous catheter for daily blood withdrawals. During the 7 post operative days the animals were observed for any behavioral changes and underwent blood withdrawals on post-operative days 1, 2 and 7. The animals were subsequently humanely sacrificed on post-operative day 7 to examine for any pathological evidence of reperfusion injury in the brain, kidney, lung and liver.
- Serum electrolyte concentrations by post-operative day 7 had been restored to within normal levels for all experimental groups except for elevation of the sodium ion concentration in the LR group pigs. Anion gap and Strong ion difference was within normal limits in all groups of pigs by post-operative day 7.
- Enzyme levels were elevated during post-operative days 1 and 2 but returned to baseline levels by post-operative day 7. No significant change in blood clotting parameters was observed during the seven day experimental period (see, FIG. 13 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
- This application is a continuation application and claims the benefit of priority from U.S. application Ser. No. 14/540,597, filed Nov. 13, 2014, which is a divisional application of U.S. application Ser. No. 12/667,309, filed Dec. 30, 2009, which is the National Phase application of International Application No. PCT/GB2008/002268, filed Jul. 3, 2008, claiming benefit of United Kingdom Application No. 0712833.3, filed Jul. 3, 2007. These applications, in their entirety, are incorporated herein by reference.
- The invention relates generally to body fluid expanders. In particular, the invention relates to physiological liquid media for use in expanding, maintaining or replacing blood or extravascular body fluid volume. It is envisaged that the invention will find use in various medical applications, including in intravenous and extravascular (e.g. peritoneal) infusion procedures.
- Loss of blood volume, also known as hypovolemia, can result, for example, from a number of causes including physical injury, surgery, internal haemorrhaging or burns. Hypovolemia can also be induced by the intake of drugs such as diuretics and vasodilators.
- A significant loss of blood volume resulting from hypovolemia can be fatal unless treated rapidly. Such blood loss leads to a drop in blood pressure and a reduction in the necessary supply of blood (and with it oxygen) to essential organs and tissues. Consequently hypovolemia can result in ischemia, multiple organ failure, kidney damage, brain damage, and ultimately death.
- Hypovolemia is treated by perfusing the subject with crystalloid or colloidal fluids as a substitute for blood lost following hemorrhagic incidents. These fluid substitutes act to expand blood volume, bring about rehydration and normalise blood pressure.
- Examples of currently known blood substitutes or blood volume expanders include lactated Ringer's solution, Hartmann's solution, HES (hydroxylethyl starch) and isotonic saline (sodium chloride) (Chiara et al.; Crit Care Med. 2003; 31(7): 1915-22; Rhee et al.; J.Trauma. 1998;. 44(2): 313-319; Jernigan et al.; Am Surg. 2004; 70(12): 1094-8; Via et al.; J.Trauma. 2001; 50:1076-82).
- Despite their ability to restore blood volume, the current blood volume expanders are ineffective at preventing a severe and often fatal condition known as reperfusion injury. This phenomenon is observed in subjects who have suffered from severe hypovolemia and manifests itself in the form of damage to essential organs (such as lungs, kidneys, liver, etc). The deleterious effects of reperfusion injury are usually observed between 1 to 3 days following perfusion with blood volume expanders.
- We have identified a need to develop further solutions which are capable of compensating for the loss of blood and the loss of interstitial and extracellular fluid resulting from hypovolemia and severe burns. There is also a need to develop treatments which are effective at preventing or lowering the incidence of reperfusion injury in hypovolemic subjects.
- In addition to the above, there is also a need to maintain a sufficient volume of extravascular, interstitial fluid. This fluid, which bathes and surrounds cells, is essential to maintaining the homeostasis of tissues and organs, and functions, inter alia, as a means of delivering materials to cells, removing metabolic waste, and facilitating effective intercellular communication.
- The present invention also addresses the significant and important problem of replacement fluid treatments resulting in oedematous conditions within body organs, thereby simply augmenting the incidences of reperfusion injury. The invention is concerned to provide a physiological balanced fluid that complies with the composition of the interstitial fluid in all aspects, but most importantly in terms of tonicity and osmolality, and would facilitate a more natural dynamic fluid exchange between the extravascular space and interstitial phase in conjunction with the lymphatic system, thereby preventing the occurrence of oedema in surrounding tissues.
- In one aspect, the invention provides a non-inorganic-phosphate-buffered body fluid expander solution, that is to say a buffered body fluid expander solution in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprising calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1.
- In another aspect, the invention provides a body fluid expander solution, comprising a non-phosphate buffer which is selected from the group consisting of physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 20° C., and most preferably from the group consisting of N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof
- In yet another aspect, the invention provides a body fluid expander solution, comprising calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1, and further comprising a non-phosphate buffer which is selected from the group consisting of physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 20° C., and most preferably from the group consisting of TES, MOPS, BES and combinations thereof.
- In one embodiment, the non-phosphate buffer is present at a concentration of from 1 to 12 mmoles/L, preferably about 5 mmoles/L
- The body fluid expander solutions of the invention preferably comprise calcium ions and magnesium ions at a concentration ratio of from 4:1 to 2:1, more preferably about 3:1.
- Preferably, the body fluid expander solutions of the invention comprise from 0.1 to 2.5 mmoles/L calcium ions and/or from 0.4 to 25 mmoles/L magnesium ions. The higher concentrations of magnesium ions, towards 25 mmoles/L, are useful for modifications of the solution for cardioplegic purposes, but for regular use as a body fluid expander solution the concentrations noted below are recommended.
- In one embodiment, the body fluid expander solutions comprise calcium ions at a concentration of from 1.0 to 2.5 mmoles/L, preferably from 1.1 to 1.4 mmoles/L, more preferably from 1.2 to 1.3 mmoles/L, even more preferably about 1.25 mmoles/L.
- The body fluid expander solutions of the invention preferably comprise magnesium ions at a concentration of from 0.2 to 0.6 mmoles/L, more preferably from 0.3 to 0.5 mmoles/L, even more preferably about 0.45 mmoles/L magnesium ions.
- In one embodiment, calcium and magnesium ions are present at a concentration of about 1.25 mmoles/L and about 0.45 mmoles/L respectively.
- In one embodiment, the body fluid expander solutions of the invention are blood substitutes for expanding and/or replacing blood volume. In yet a further embodiment, the body fluid expanders are extravascular fluid substitutes, e.g., interstitial fluid substitutes.
- In addition to the above, the invention also encompasses concentrated forms of the solutions defined herein. For example, 1 to 50×, preferably 5 to 20× concentrates are encompassed. In order to produce a solution of 1×, that is to say working strength, concentration, 5×, 10×, 20× and 50× concentrates require, respectively, 4, 9, 19 and 49 volumes of water to be added to one volume of concentrate, plus the equivalent of 2.1 g of sodium hydrogen carbonate per litre of the diluted 1× solution.
- In another aspect, the invention provides solutions as defined herein for use as medicaments and blood volume expanders.
- In a further aspect, the invention provides solutions as defined herein for use in treating hypovolemia and/or bums, and for use in preventing and/or ameliorating reperfusion injury.
- In yet a further aspect, the invention provides solutions as defined herein for use in: (a) fluid replacement therapy, (b) perfusing a body cavity (e.g. the abdominal or thoracic cavity) of a subject undergoing a surgical procedure, and/or (c) intravascular or extravascular delivery of therapeutic, test and/or synergistic agents to a subject.
- The invention also encompasses the use of a solution as defined herein for the manufacture of medicaments and blood volume expanders, e.g. for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with bums.
- The invention also provides the use of a solution as defined herein for the manufacture of a medicament for (a) treating the loss of interstitial fluid in a subject suffering with burns, (b) treating respiratory and/or metabolic acidosis in a subject, (c) perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, or (c) preventing and/or ameliorating reperfusion injury.
- In yet a further aspect, the invention encompasses uses of solutions of the invention for delivering a therapeutic, test and/or synergistic agent to a subject, for example a biological agent, such as at least one stem cell, peptide or genomic derived protein.
- In preferred embodiments, the delivery is effected by administration via an intravascular, intraperitoneal, intradermal, oral, intramuscular or topical route. Optionally, the delivery is effected by administration to the lymphatic system of a subject.
- In yet a further aspect, the invention encompasses methods of treating hypovolemia and/or burns, and methods of preventing and/or ameliorating reperfusion injury, these methods comprising administering to a subject in need thereof an effective amount of a solution as defined herein.
- In preferred embodiment instances the hypovolemia results from dehydration and/or burns and/or bleeding. In another embodiment, the hypovolemia is drug induced.
- In a further aspect, the invention provides a method of maintaining physiological homeostasis of a tissue and/or organ in situ during a surgical procedure carried out on a subject, the method comprising perfusing said tissue and/or organ with a solution as defined herein.
- In one embodiment of the above method, the solution is maintained at a temperature of between 4 and 20° C. such that said tissue and/or organ, when perfused with said solution, is maintained in a state of hypothermia.
- In yet a further embodiment of the above method, the surgical procedure is carried out to retrieve said tissue and/or organ from a donor subject, for subsequent transplantation to a recipient subject.
- In yet another aspect, the invention encompasses methods for delivering a therapeutic, test and/or synergistic agent to a subject using the solutions of the invention. In a preferred embodiment, the agent is a biological agent, such as at least one stem cell, peptide or genomic derived protein.
- In preferred embodiments, the delivery is effected by administration via an intravascular, intraperitoneal, intradermal, oral, intramuscular or topical route. Optionally, the delivery is effected by administration to the lymphatic system of a subject.
- In another aspect, the invention provides the use of a solution as defined herein for (a) dialysis of the peritoneal cavity in a subject suffering from acute renal failure or an acute toxicity condition; and/or (b) irrigation of abdominal and/or thoracic organs in a subject undergoing a surgical procedure.
- In yet another aspect, the invention encompasses a substantially inorganic-phosphate-free buffered solution for use as a medicament, especially one that is also substantially free of at least one of citrate and lactate buffer
-
FIG. 1 Assessment of the survival of rats over time as a function of the resuscitation solution used. Rats were subjected to serial withdrawals of blood. The rats were separated into three experimental treatment groupings as follows: (1) replacement of blood with physiological saline; (2) replacement of blood with a preferred solution in accordance with the invention, referred to herein as RS-I solution or RS-I; and (3) no replacement of blood losses. Survival of rats in each of the various groupings was monitored and the data set out inFIG. 1 . -
FIG. 2 Comparison of the total volume of blood withdrawn for each of the study arms defined with reference toFIG. 1 above. Blood was withdrawn from rats as described in the Example 4 below. -
FIG. 3 Assessment of the respiratory rates of rats over time in the various study arms defined with reference toFIG. 1 . -
FIGS. 4A, 4B, 4C, 4D, 4E and 4F : Assessment of pig blood profiles over various time periods of perfusion with RS-I. Pigs were infused with 1.0 L of RS-I solution every day for three days and blood samples were taken at various time points. Blood samples were tested, inter alia, for complete blood counts, serum chemistry determination, electrolytes, glucose, lactate, osmolality, serum enzymes (serum glutamic oxaloacetic transaminase/aspartate aminotransferase [SGOT/AST], serum glutamic pyruvic transaminase/alanine aminotransferase [SGPT/ALT], creatine kinase [CK] and lactate dehydrogenase [LDH]), coagulation factors and fibrinogen levels. Also, blood was measured for interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). -
FIG. 4G Summary Data Table re Blood Data Analysis in a Normovolemic Pig model. -
FIGS. 5A, 5B,5C, 5D, 5E, 5F and 5G : Analysis of Serum Electrolyte Levels in a Normovolemic Pig model -
FIGS. 6A, 6B, 6C and 6D Analysis of Serum Metabolites Levels in a Normovolemic Pig model -
FIGS. 7A, 7B, 7C and 7D Analysis of Serum Enzyme Levels in the a Normovolemic Pig model -
FIGS. 8A, 8B, 8C, 6D and 6E Analysis of Blood Cell Profiles in a Normovolemic Pig model -
FIGS. 9A, 9B, 9C and 9D Analysis of Blood Clotting Parameters in a Normovolemic Pig model -
FIG. 10 Comparison of the ADP:ATP (adenosine diphosphate: adenosine triphosphate) ratios in cold static (CS) and warm static (WS) group pig kidneys before and after 6 hours of normothermic perfusion. -
FIG. 11 Change in the mean Arterial Pressure following resuscitation in Autologous Blood, RS-I fluid and Lactated Ringer's saline -
FIG. 12 Activated Prothromboplastin Time (aPTT) following resuscitation in Autologous Blood, RS-I fluid and Lactated Ringer's saline -
FIG. 13 Activated Partial Thromboplastin Time (aPTT) during Experimental Period - The terms “body fluid expander” or “body fluid expander solution” or “body fluid substitute” as used herein mean a physiological liquid solution which is intended for use in replacing or expanding body fluid, and/or maintaining a sufficient volume of body fluid. The body fluids for which the solutions of the invention are intended to expand, replace or maintain include intravascular fluids (e.g. blood components such as plasma), or alternatively, extravascular fluids (e.g. interstitial fluid).
- The terms “body fluid expander” and “body fluid expander solutions” also encompass physiological liquid media which are intended for use as a vehicle for the delivery of therapeutic, test and/or synergistic agents into the body of a subject in need of said agents, or in circumstances where the agents are to be tested, for example on non-human subjects.
- The term “subject” or “subjects” encompasses, where appropriate, human subjects and non-human animal subjects, for example mammalian subjects such as rodents, pigs, monkeys, dogs and the like as appropriate in experimental research and cattle, horses and the like as occurs in veterinary practice.
- Terms such as “non-phosphate buffer” and “substantially phosphate free” are intended to encompass fluid embodiments which substantially lack inorganic phosphate ions.
- The terms “blood volume expander” or “blood volume expander solution” or “blood substitute” as used herein mean a physiological liquid solution which is intended for use in replacing, expanding or maintaining blood volume. These solutions therefore find use in substituting for a loss of blood volume resulting from hypovolemia.
- The term “hypovolemia” as used herein means a state of decreased blood volume, or more specifically, a state of decreased blood plasma volume. Common causes of hypovolemia include dehydration, burns, bleeding (e.g. haemorrhaging) or the intake of certain drugs such as diuretics and vasodilators.
- The term “reperfusion injury” as used herein means the injury caused to essential organs of the body following hypovolemia and subsequent perfusion with conventional blood volume expanders.
- The present invention emerges from a realisation of the inventor that conventional blood volume expanders are detrimental to the maintenance of cell, tissue and organ survival and viability, and can hence contribute to the development of reperfusion injury.
- In part, the present invention stems from an appreciation that the composition of blood volume expanders (and physiological media in general) should be based on a specific knowledge of the activity coefficients of ionic species within the interstitial gel phase surrounding each cell. These activity coefficients have been calculated and the solutions of the present invention have been designed in accordance with these calculations.
- The solutions of the invention make use of non-phosphate buffers, based on the realization that excess phosphate ions can be deleterious to the viability and functional integrity of perfused cells, tissues and organs. Phosphate ions inhibit glycolysis, oxidative phosphorylation (Berman & Sanders; Circul.Res., 1955; 3, 559-563), creatine kinase activity (Hall & DeLuca; Adv. Exp. Med. Biol. 1986; 194, 71-82) and the enzymes involved in oxygen free radical scavenging (De Frietas & Valentine; Biochemistry 1984; 23:2079). These enzymes are important in inducing apoptotic changes at the cellular level, ultimately leading to the necrosis (i.e. death) of damaged or abnormal cells, tissues and organ systems.
- Essentially, the use of non-phosphate buffered solutions avoids the inefficiency of conventional phosphate buffered solutions in terms of instability above pH 7.2. In particular, inorganic phosphate ions in conventional solutions are, over time, precipitated in the form of insoluble calcium phosphate (Pedersen, MD Thesis, University of Arhus, Denmark. Publ. S A Moller Christensen A/S. 1973; 41-51). This problem is accentuated by variations in the temperature range at which the solutions are used and therefore such conventional buffered solutions are of limited clinical utility. Furthermore, a number of other non-phosphate buffer agents, e.g., citrates, certain amino acid combinations, and lactated solutions, are distinct from the natural or physiological pH buffer agents operating in mammalian species and have been found to be ineffective in preserving organ function under ex vivo (see, EXAMPLE 6) and in vivo (see, EXAMPLE 8) normothermic conditions. In contrast, the solution of the invention, when in use as a body fluid expander, has enhanced performance because it is capable of utilising the natural buffer system found in all mammals, namely, a pCO2/hydrogen carbonate system.
- Described herein are body fluid expander solutions which, by virtue of their composition, are able to compensate either for loss of blood in hypovolemic subjects, or loss of interstitial and extracellular fluid associated with severe burns. The body fluid expander solutions of the invention provide physiological liquid media which mimic the ionic, substrate and biophysical environment of interstitial fluid (see, for example, Table II below). As such, it is envisaged that these solutions will find use as universal perfusion and preservation media. The concentrations of ion species acknowledge the activity coefficients of each ionic species within the interstitial gel phase around mammalian cells. This is in contrast to many conventional media which base their concentrations on total serum concentrations.
- In U.S. Pat. No. 6,946,241 (which is incorporated herein by reference), the present inventor describes non-phosphate buffered liquid cell culture media. It has now been appreciated that effective blood volume expander solutions and body fluid expander solutions in general can be based on the composition of these media. It is envisaged that the solutions of the present invention will not only compensate for the loss of blood associated with hypovolemia but will also reduce or prevent the onset of reperfusion injury. It is also envisaged that the solutions defined herein will have application in the in situ maintenance of organs and tissues, which become exposed during various surgical procedures.
- The body fluid expander solutions of the present invention are preferably free of serum and/or serum components. The solutions are hence free of animal derived serum proteins and other contaminants, such that there are no undefined, extraneous serum proteins present. The absence of serum has the advantage that the solutions are “chemically” better defined than conventional serum based solutions. Furthermore, the absence of serum and serum derived components avoids concerns over the possible transmission of infectious diseases (e.g. Human immunodeficiency virus (HIV) and Creutzfeldt-Jakob disease (CJD) associated with the use of this material in vivo.
- For the reasons given above, the body fluid expander solutions of the present invention (and particularly those solutions intended for human use) are also preferably free of foreign or animal derived antigens, pyrogens, proteins and the like. However, in certain situations, e.g. dialysis, susceptible patients may require the presence of specific peptide or protein derived components as a compensatory measure for the reported loss of proteins during renal or peritoneal dialysis. The solutions of the invention may provide effective vehicles for use in delivering such components to patients.
- A major discovery that has evolved during work with solutions similar to the solutions of the present invention in isolated tissue and organ perfusion experiments is that they can utilise the natural pH buffering mechanisms observed in all mammalian species, namely, auto-regulation of the partial pressure of carbon dioxide [pCO2] and concentration of the bicarbonate ion [HCO3
- As previously stated, the body fluid expanders of the present invention adopt and take advantage of a natural physiological buffering system. Preferably this buffering system takes the form of NaHCO3/pCO2 (sodium hydrogen carbonate/dissolved CO2) in combination with the zwitterionic Good's buffer, BES (N, N-bis [2-Hydroxyethyl]-2-amino-ethanesulphonic acid (Good et al.; Biochemistry 1966; 5:467-477), incorporated herein by reference), which acts by virtue of its ideal pKa over a temperature range of 10 to 37° C., to provide a stable pH, an essential requisite for cellular preservation. BES has been shown to be non-toxic to cultured mammalian cells in long term studies and exhibits negligible binding of calcium or magnesium ions, so removing the potential hazard of precipitation of divalent ions which occurs when using conventional hydrogen carbonate/phosphate or double phosphate buffer solutions. Indeed, 10× concentrates of solutions according to the invention have been experimentally shown to have a shelf life (stored at 3 to 8° C.) in excess of 14 months. As alternatives to the use of BES, it is also possible to use morpholinopropane sulphonic acid (MOPS) or N-tris-(hydroxymethyl) methyl-2-amino ethane-sulphonic acid (TES). Furthermore, a combination one or more of TES, BES and MOPS could be used.
- Other physiologically acceptable N-substituted aminosulfonic acid buffers may be chosen according to specific requirements, and the following Table lists potential candidates and their pKa values in aqueous solution at 20° C.
-
pKa @ -ΔpKa/ N-substituted Aminosulfonic Acid Buffer Agents 20° C. ° C. MES: 2-(N-morpholino) ethanesulfonic acid 6.15 0.011 ADA: N-(2-acetamido) iminodiacetic acid 6.62 0.011 ACES: N-2-(acetamido)-2-aminoethanesulfonic acid 6.88 0.02 BICINE: N,N-bis (2-hydroxyethyl) glycine 8.35 0.018 BES: N,N-bis (2-hydroxyethyl)-2- 7.15 0.016 aminoethanesulfonic acid HEPES: N-(2-hydroxyethyl) piperazine-N′-(2- 7.55 0.014 ethanesulfonic acid) MOPS: 3-(N-morpholino) propanesulfonic acid 7.20 0.011 PIPES: piperazine-N,N′-bis(2-ethanesulfonic acid) 6.80 0.009 TES: N-tris(hydroxymethyl) methyl-2- 7.50 0.020 aminoethanesulfonic acid TRIS: tris(hydroxymethyl) aminomethane 8.3 0.031 TRICINE: N-tris(hydroxymethyl) methylglycine 8.15 0.021 - Optionally, the non-phosphate buffer (preferably TES, MOPS or BES, or combinations thereof) is present at a concentration of from 1 to 12 mmoles/L, preferably from 3 to 7 mmoles/L, more preferably from 4 to 6 mmoles/L, even more preferably about 5 mmoles/L. Optionally, hydrogen carbonate ions are present at a concentration of from 21 to 35 mmoles/L, preferably from 23 to 26 mmoles/L, more preferably about 25 mmoles/L.
- In preferred embodiments of the invention, the non-phosphate buffer systems used allow, because of their unique pKa range, the ability to automatically adjust the pH of the solutions of the invention from 7.05 to 7.5 over a temperature range of from 4° C. to 38° C. This feature of the invention, unlike that found with conventional buffering systems, does not require any further intervention in adjusting the pH to give values ranging from 7.13 to 7.5±0.5 over a temperature range of 10 to 38° C. Preferably, the solutions of the invention have a pH of about 7.46 at a temperature of about 37.4° C. It is preferred that the above pH values are maintained in vivo following administration of the solutions to a subject in need thereof.
- As discussed herein, the solutions of the invention may be used for both intra- and extravascular infusion procedures. The solutions may also be used to perfuse isolated animal and human organs under normothermic conditions. When the solutions are used to perfuse isolated organs, it is preferable that the solutions are aerated with carbogen gas (95% oxygen/5% carbon dioxide).
- The body fluid expander solutions of the present invention may also comprise in any combination, one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, or all of the following components: from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) μmoles/L glycerol, from 7 to 15 (preferably about 10) μmoles/L choline, from 5 to 400 (preferably about 300) μmoles/L glutamate (preferably L-glutamate), from 5 to 200 (preferably about 20) μmoles/L aspartate (preferably L-aspartate), from 100 to 2000 (preferably about 400) μmoles/L glutamine (preferably L-glutamine), from 15 to 215 (preferably about 60) μmoles/L pyroglutamate, from 20 to 200 (preferably about 100) μmoles/L arginine (preferably L-arginine), from 1 to 120 (preferably about 40) nmoles/L thiamine pyrophosphate (TPP), from 40 to 70 (preferably about 50) μmoles/L D- or DL or L-carnitine (preferably L-carnitine), and from 5 to 200 (preferably about 28) mI.U./L porcine or human insulin (preferably human insulin).
- Chloride ions, when present, are preferably provided as sodium, potassium, calcium and magnesium salts. Preferably, when present, choline is provided as a chloride salt.
- Solutions encompassed by the present invention comprise a number of substrates which retain metabolic homeostasis of tissues and organs. Glucose and glycerol have been shown to be satisfactory in meeting the energy demands of isolated tissues and organs, even when they are not the preferred substrate for the organ in question (e.g. the heart) by the inclusion of physiological levels of insulin. Apart from their ability to be metabolized, glycerol and glucose also have free radical scavenging and membrane stabilizing properties, which have been shown to be extremely important in maintaining the physiological viability of tissues and organs.
- As described above, aspartate and glutamate can also be included in the solutions according to the invention, to enhance oxidative metabolism by replenishing tricarboxylic acid (TCA) cycle intermediates, thereby maintaining high energy phosphate levels even during ischemic insult. Similarly, glutamate is involved in maintaining intracellular oxidation-reduction potentials. It is envisaged that by optimizing the aspartate-malate and glycerol phosphate shuttles, cells will maintain an optimal NAD/NADH (nicotinamide adenine dinucleotide/reduced nicotinamide adenine dinucleotide) balance and thereby sustain adenine nucleotide levels. In addition, glutamate and glutamine can act as intermediary metabolites to form pyroglutamate and thereafter participate in the gamma-glutamyl cycle to synthesise glutathione, a beneficial agent in preventing the generation of toxic oxygen radicals associated with the incidence of reperfusion injury in mammalian tissues and organs during storage of donor organs prior to transplantation and following blood volume replacement therapies.
- Thiamine plays an important role in the oxidation of α-keto acids (by the action of thiamine cocarboxylase) and prevents the accumulation of pyruvate and toxic pyruvate aldehyde, thereby minimizing cellular apoptosis and accompanying necrosis of tissues and associated organs.
- In the TCA cycle, thiamine pyrophosphate (TPP), which is included in preferred solutions of the invention, is a co-factor in the metabolism of a-ketoglutaric acid to form succinyl-coenzyme A, by oxidative decarboxylation, or to form glutamate, by reductive amination. In essence, TPP is involved in numerous interrelated biochemical pathways, especially those of the Pentose Phosphate and Glycolytic pathways. The thiamine may be employed as thiamine pyrophosphate, thiamine diphosphate or thiamine diamide. Preferably the solutions of the invention comprise thiamine as thiamine pyrophosphate chloride.
- Further, the inclusion of thiamine pyrophosphate in the formulation of the solutions of the invention would also appear to be of necessity to peritoneal dialysis patients in order to prevent phosphate ion depletion and calcification as it is readily dialyzable across hemodialysis membranes (MW—175 Dalton) and has been previously administered either intravenously or via the hemodialysis or peritoneal dialysis solution to replenish plasma phosphate and/or pyrophosphate levels.
- The vitaminoid carnitine has been reported to have multiple effects in improving cardiac function other than by simply optimizing oxidative metabolism, such as, by promoting the utilization of alternative substrates and may additionally improve coronary blood flow. L-carnitine is preferred to the D- or DL isomers because it causes no inhibition of acetyl co-enzyme A/free fatty acid metabolism. Preferably the vitaminoid component comprises 50 μmoles/L of [-]-β-hydroxy-γ-trimethylamino-butyrate hydrochloride (L-carnitine). In this invention, the preferred inclusion of the L-isomer of carnitine is intended to optimise the transport of long chain fatty acids from the cytosol into the mitochondrial matrix to the site of 13-oxidation and thereby to buffer the intramitochondrial acetyl CoA/CoA ratio (where CoA is Coenzyme A) by stimulating the synthesis of acetyl carnitine from carnitine acetyl transferase. This reduction in the ratio of acetyl CoA/CoA will result in an efflux of acetyl carnitine from the mitochondria with an associated stimulation of pyruvate dehydrogenase and reversal of fatty acid inhibition of glucose oxidation. Ultimately the optimization of free fatty acid utilization as an energy source is essential for all types of cells but this must be done with preservation of carbohydrate (glucose) utilization by optimized functioning of the enzymes involved in glycolysis, eg. hexokinase, glucokinase, phosphofructokinase.
- As described above, solutions of the invention may also comprise insulin. The use of human recombinant insulin (e.g. expressed in E. coli or S. cerevisiae) not only precludes the risk of antigenic or viral contamination in recipient cells/tissues/organs, as may be the case with insulin derived from other mammalian or animal sources, but also leads to a better fit being achieved of insulin molecules to human insulin receptor structure, i.e. Receptor specificity will be optimized to retain the many associated functions of insulin in cellular processes.
- Essentially, the biological effects of insulin do not simply relate to its ability to regulate carbohydrate metabolism and facilitated transport of circulating glucose into cells but also in its ability to bring about (i) the enhancement of intracellular glucokinase activity and amino-acid incorporation into protein, (ii) stimulation of DNA (deoxyribose nucleic acid) translation into proteins, (iii) increased lipid synthesis and (iv) stimulation of sodium, potassium and inorganic phosphate transport across cell membranes.
- In preferred embodiments of the invention, normal, human serum levels of insulin have been utilized. In contrast, conventional known perfusate formulations have, when incorporating insulin, made use of unnatural levels of this hormone (e.g. 10 to 50×106 mIU/L; about a million times more concentrated that the insulin found in solutions of the invention). The reason for this relates to the fact that only a small amount of the insulin exists as single molecules in such concentrations. The rest of the insulin exists in the form of large aggregates, which are ineffective at stimulating insulin receptors and are hence biologically inactive. The solutions of the invention achieve normal, human serum levels of insulin by acidifying the insulin during formulation to prevent aggregate formation, so allowing individual active, molecular species of insulin to exist in solution at pH 7.3±0.2.
- The concentrations of ionic species in solution according to the invention acknowledge the activity coefficients of each ionic species and not simply their total serum concentrations. For example, serum binding of calcium and magnesium ions must be distinguished from the actual free, ionized levels of these ions. Magnesium ions are important in a number of critical cellular reactions and their extracellular presence is reported to stimulate mitochondrial respiratory activity and modulate the effects of rapid calcium influx and potassium efflux. Equally, an adequate concentration of calcium ions is important to maintain the free levels of this ion present in the circulation.
- The ionic conductivity of the solutions of the invention is preferably comparable to that of human serum, namely 12.0±0.3 mS cm−1 and as such maintains the ionized status of the cell membrane and activities of enzymic moieties.
- Thus in accordance with the above, the solutions of the present invention are isosmotic to human serum (ca. 290 mOsmoles/L) and do not appear to necessitate the inclusion of plasma expanders, as demonstrated by the fact that only minor changes (ca. 8%) in hydration occur during long term (i.e. 4 to 52 hr) hypothermic perfusion of the isolated rat heart and visceral nerve-muscle preparations. This may be explained by the fact that the cell membrane lies in continuity with a 99% gel interstitial phase so providing natural colloidal buffering to excess Donnan ionic equilibrium exchange across the cell membrane. The majority of the osmotic pressure is provided by sodium ions and their accompanying anions, and only a small component (ca. 0.5%) can be attributed to plasma proteins. The inclusion of serum levels of the metabolite, glycerol, in this solution may also contribute to osmotic buffering at the interstitial fluid interface surrounding each cell, specifically that involving the transcapillary network.
- The practicality of including oncotic agents is further compromised by their affinity for calcium and magnesium ions, necessitating prior dialysis in fresh solution so as not to disturb cationic composition. The labile nature of polypeptide expanders also makes them impractical through their predisposition to mechanical denaturation. Unfortunately, while these colloidal expanders are essentially non-toxic, their use is contraindicated in terms of, for example, (1) raised viscosity increases the thickness of the ‘unstirred’ layer around cells so hindering diffusion of metabolites, (2) alteration of the surface membrane bioelectric potential so disrupting cellular metabolism and receptor activities, (3) antigenicity of proteinaceous expanders, (4) agglutination and haemolysis of red blood cells (RBC's) and (5) blockage of microvasculature and ischemia.
- It is envisaged that the solutions of the invention will find general use as base compositions to which additional components can be added, depending upon the specific medical purpose. For instance, it is envisaged that the solutions of the invention could be supplemented with, for example, red blood cells (RBC's), plasma and/or platelets for the generation of artificial blood. Such blood components may be either natural or artificial. Thus, additional chemicals can be added to the base composition as and where required. It is therefore intended that the solutions of the invention will find broad applicability as base compositions where a medical utility requires the expansion, replacement, maintenance and/or supplementation etc of a body fluid with a buffer agent whose pKa closely matches and behaves like that of imidazole/histidine moieties of hemoglobin (pKa: 7.0) so precluding the use of citrate (pKa: 3.09), lactate (pKa: 3.85) or any similarly unsuitable pKa buffer agent as well as inorganic phosphate ions with their reported deleterious effects on biochemical and physiological processes.
- The solutions of the invention find use in methods for treating hypovolemia or the loss of interstitial and extracellular fluid brought about in subjects suffering from severe burns. In addition, the solutions of the invention are applicable in methods of preventing and/or ameliorating reperfusion injury. The solutions of the invention therefore find use as medicaments. For treating hypovolemia and for preventing/ameliorating reperfusion injury, it is preferable to systemically administer the solutions of the invention by the intravenal route. In such instances, the patient will be placed securely in a recumbent position and clinically prepared for the intravenal administration of the specific medicament adopting conventional, clinical procedures. Delivery of the said medicament to the patient will be executed under controlled, supervised conditions until completion of the treatment is achieved.
- However, in addition to replacing, maintaining or expanding blood volume, it is envisaged that the solutions of the inventions will also find other uses which include the following; for maintaining, preserving and irrigating tissues and organs in situ during surgical procedures, for perfusing the abdominal cavity of a subject suffering with an acute renal failure or an acute toxicity condition, and for preserving donor tissues and organs in situ during surgical procedures for their removal from the donor patient. Thus, as well as being administrable through the intravascular route, the solutions of the invention may also be administered by other routes, for example, using intraperitoneal, intradermal, intramuscular, topical or oral routes. In patients with acute renal failure or acute toxicity, the patient will be prepared under anesthesia for surgical intervention whereby cannulae will be inserted into the peritoneal cavity, secured in position to ensure the continuous irrigation with the solution under normothermic temperatures. Removal of the peritoneal cannulae will be performed under surgical conditions once normalcy has been achieved in the patient's blood chemistry analysis.
- For the treatment of burns, it is preferable to administer the solutions locally by topical application to the site of the burn itself. In addition however, dehydration brought about as a result of severe burns can be treated through systemic administration of the solutions. In such circumstances, the patient will be placed securely in a recumbent position and clinically prepared for the intravenal administration of the specific medicament adopting conventional, clinical procedures. The location and degree of burn involvement will be assessed in terms of the intravenal site administration of the solution and the requirement for additional therapeutic agents based upon the risk of further infection. This method of therapeutic treatment will result in an outward, extravascular flow of the solution so removing any build up of toxic or infective fauna exudates and thereby require constant monitoring of surgical dressings. In preferred embodiments, the methods, solutions and medicaments of the invention are for use in treating human and non-human mammalian subjects, e.g., humans.
- As mentioned above, it is envisaged that one application of the solutions defined herein is for preserving donor organs in situ before, during and after surgical procedures for their removal from the donor subject. Use of the solutions of the invention in this regard could involve, for example, whole body infusion (Extra Corporeal Membrane Oxygenation [ECMO] procedure) with donor kidneys, heart, liver, etc being harvested from a donor cadaver followed by normothermic reperfusion of the isolated organ. Preliminary studies (not shown here) have indicated that RS-I as defined herein (see Examples) has the ability to re-animate hypothermically preserved cadaver human organs allowing such organs to be used in preclinical drug bioassay trials, thereby addressing the problem of Adverse Drug Reactions (ADR) reported to occur using in vitro and in vivo drug assessment in animal models.
- It is also envisaged that the solutions of the invention will find use as media for the effective delivery of agents to a subject in need thereof, or in circumstances where the agents are to be tested, for example on non-human subjects. For example, the solutions of the invention may find use as diluents for the delivery of pharmaceutical, test or synergistic agents or, alternatively, for the delivery of stem cells, peptide or genomic derived protein. to a subject in need thereof The delivery of stem cells could, for example, be brought about by suspending the stem cells in media as defined herein, and delivering the resulting suspension directly to the tissue or organ where required. Under this therapeutic regime, patients will undergo surgical removal of derivative stem cell types, e.g., cardiomyocytes, hepatocytes, which may then be suspended in the solutions of the invention and pre-incubated for 12-18 hours. Further proliferation of the stem cell type will be conducted using current culture media techniques whereafter the cells will be re-suspended in the solution and transported to the patient's bedside under hypothermic or mild hypothermic conditions prior to execution of the therapy. Patients will undergo local or general anesthesia dependant upon the route of administration of the stem cell-derived therapy, e.g., local anesthesia for intramyocardium administration of cardiomyocytes, and the administration of the therapy conducted at normothermic temperatures under good clinical practice. Alternatively, delivery may be effected by administration of the suspension to the lymphatic system.
- It will be appreciated that the general methods of administering blood volume expanders, known in the art, can be applied when using the solutions of the invention. In particular, methods for regulating the level of administration required in a particular situation (eg. by reference to maintaining adequate blood pressure and cardiovascular function) can be applied using the information available to the skilled person, having regard to the state of the art.
- It will be further appreciated that standard perfusion techniques, known in the art, for bathing and irrigating tissues and organs in situ during surgical procedures and for dialyzing body cavities, can be applied when utilizing the solutions of the present invention.
- The invention envisages that specific sub-components of the solutions of the invention can be used individually or in any combination.
- Particular embodiments of the invention are described below by way of the following examples. The examples are provided to illustrate embodiments of the invention but are not to be considered as limiting in any way.
- EXAMPLE 1: Formulation of RS-I Solution
- In the following preparations, endotoxin-free Milli-Q purified water (Millipore Corp, Milford,
- MA) or equivalent ASTM Type I water [resistivity no more than 18.0 MΩ-cm at 25° C.] was used throughout, both in the initial stirring, and in the final dilution. The term ‘purified water’ is used hereinafter to denote water of this quality.
- Thiamine pyrophosphate (cocarboxylase), Sigma C4655 was prepared as a 0.4 mg/mL stock solution in purified water and stored frozen in dark glass vials. Choline chloride (Sigma C7527) was prepared as a 17.5 mg/mL stock solution in purified water and stored frozen in glass vials. Human recombinant insulin (Sigma 10259/12643) was prepared as a 0.5 I.U./mL stock solution in purified water acidified to pH 2.4 with 0.12N hydrochloric acid and stored frozen in glass vials.
- For the preparation of a 10× concentrate solution of RS-I solution, a stainless steel container was filled with 8 litres of purified water and, the following ingredients were weighed out and added while constantly stirring, in the following order: 642.96 grams of sodium chloride (CFK0484), 37.28 grams of potassium chloride (BDH10198), 18.38 grams of calcium chloride dihydrate (BDS10117), 9.14 grams of magnesium chloride hexahydrate (BDH101494) and 106.61 grams of BES free acid (Sigma B6266), 1.84 milligrams of thiamine pyrophosphate (Sigma C9655) (using 4.6 mL of the stock solution), 0.9899 grams of L-carnitine (Sigma C0238), 0.1397 grams of choline chloride (Sigma 7527) in the form of 8 ml of the stock solution, 1.013 grams of glycerol (Sigma G2025), 2.8 I.U. of human recombinant insulin (5 ml of the stock solution), 0.310 grams of L-aspartate sodium salt (Sigma A6683), 180.2 grams of anhydrous D-glucose (Sigma G7021), 5.07 grams of L-glutamate sodium salt (Sigma G5889) and 5.84 grams of L-glutamine (Sigma G5763). The whole was stirred until completely dissolved and then the final volume of 10 litres was produced by adding further purified water.
- The 10× RS-I solution was sterile filtered through a Sartobran PH2O cartridge/0.2 micrometer filter (Sartorius Corp. USA) into 100 mL sterile sealed glass bottles.
- This RS-I solution is a 10 times concentrate of the solution intended for use, but with sodium hydrogen carbonate withheld. When needed, the 10× RS-I solution can be diluted with the appropriate quantity of purified water, and sodium hydrogen carbonate added.
- For preparation of the 1× RS-I solution, 100 ml of the above 10 times concentrate RS-I solution may be diluted with 900 mL of purified water to 1 litre with the addition of 2.1 g of endotoxin-free sodium hydrogen carbonate (Sigma S4019) and stored at 8-10° C. prior to use. Sodium hydrogen carbonate is preferably not added to the concentrate solutions before they are stored, since extended storage of the concentrate containing hydrogen carbonate ions may cause precipitations of calcium carbonate.
Stock 1× solutions for short-term storage may contain sodium hydrogen carbonate. - For use as a body fluid expander solution, each litre of the solution may contain 100 mg/L of chloramphenicol (Sigma C3175) or other conventional antibiotics or antifungal agents to prevent the risk of bacterial infection.
- The following factors should be taken into account when preparing the solution:
- 1) The method of assembly of the solutions and, specifically;
2) Use of purified water as specified above to make up all stock solutions and the 10 times concentrate bottles of manufactured solutions according to the invention;
3) The methods of preparing sterile stock solutions according to the invention and concentrates should not involve autoclaving or gamma-irradiation. For example, irradiation of the solution to achieve sterility will result in degradation of glutamine, glucose, insulin and thiamine pyrophosphate components;
4) The use of glass bottles for storage of all 10 times stock concentrate solutions;
5) Preparation of solubilised insulin by acidification at pH 2.4 plus storing insulin ingredients and stock solutions at −20° C.;
6) Preparation of thiamine pyrophosphate plus TPP stock solutions stored at −20° C. under dark conditions (see reason below);
7) Preparation of Choline chloride stock solutions stored at −20° C.;
8) Use of magnesium chloride hexahydrate (i.e. 6H2O). This is because if the dehydrate salt is used then it adsorbs water so the weight used to calculate the precise magnesium ion content will be in error—this is a common reason for wrongly made up Krebs solutions in terms of correct magnesium ion and calcium ion levels. - The inclusion of all preferred components, as described in this Example, allows these components to work in synergy to produce an overall balanced physiological effect.
- 1. Stock solutions: Various stock concentrations of solutions according to the invention namely, 1×, 10× and 20× for long-term storage have been prepared, but the preferred stock concentrates are 10× concentrates using purified water sterile filtered into sealed 100 mL bottles for storage under dark conditions at 3 to 8° C. Stock solutions are reconstituted for use as 1× solutions by the addition of 100 mL of 10× concentrates of stock solutions to 900 mL of purified water with the addition of 2.1 g of sodium hydrogen carbonate to give a final pH of 7.22.±0.04 at 20° C.
Sterile stock 10× concentrations of solutions according to the invention have a pH of 4.6.±0.2 and have been shown to remain sterile, and free of precipitations, for periods of up to ten years. The recommended manufactured shelf-life of 10× stock concentrates of solutions according to the invention is 14 months when stored at 3 to 8° C. under dark conditions.
2. Cocarboxylase: Stock solutions of thiamine pyrophosphate chloride (cocarboxylase) are prepared at 18.4 g/mL using endotoxin-free purified water, sterile filtered into dark sealed vials to prevent the photon degradation of thiamine pyrophosphate, and stored frozen prior to the assemblage of 10× stock concentrates of solutions according to the invention.
3. Insulin: Human recombinant insulin is prepared as acidified (pH 2.4) stock concentrated solutions at 0.5 m I.U./mL using endotoxin-free purified water and sterile filtered into sealed vials and stored frozen prior to the assemblage of stock concentrates of solutions according to the invention.
4. Choline: Stock solutions of choline chloride are prepared at 17.45 mg/mL using endotoxin-free purified water and stored frozen in sealed vials prior to the assemblage of stock concentrates of solutions according to the invention.
5. Chloramphenicol is not an essential component of solutions according to the invention but is preferably added, either for storage, or after the storage vials have been opened, to ensure sterility during extended exposure of the solutions to the atmosphere and to lower the risk of infection to subjects treated with the body fluid expander solutions of the invention. - The following Table summarises the composition of RS-I solution for use as a body fluid expander.
-
TABLE I Component Concentration NaCl 110.00 mmoles/L KCl 5.00 mmoles/L CaCl2 1.25 mmoles/L MgCl2 0.45 mmoles/L NaHCO3 25.0 mmoles/L BES 5.00 mmoles/L D-Glucose 10.00 mmoles/L Glycerol 0.11 mmoles/L L-Glutamate 0.30 mmoles/L L-Glutamine 0.40 mmoles/L L-Aspartate 0.02 mmoles/L L-Carnitine 0.05 mmoles/L Choline Chloride 0.01 mmoles/L TPP (cocarboxylase) 40.00 nmoles/L Human recombinant insulin 28 mIU/L - The solution described in Examples 1 and 2 and referred to herein as RS-I represents a preferred form of the body fluid expander solution in accordance with the invention.
- At the present time, and according to the prevailing thinking in the art, the formulation of preservation, perfusate and blood volume replacement solutions is strongly inclined towards adopting the composition of either the intracellular or the extravascular milieu. However, as already noted herein, numerous problems still remain unsolved. In considering the ultrastructural of cell membranes, the inventor has departed from current thinking and taken a different approach, namely that a physiological solution should be so formulated to mimic, in a practical artificial manner, the milieu directly adjacent to the cell membrane, namely, the interstitial fluid phase, so maintaining as far as possible homeostasis and the functional dynamics of the cell membrane and associated receptor and enzyme moities. The resulting successful preservation of cellular function of isolated cells, tissues and organs from animal species and humans, demonstrated in Examples 6 and 7 herein, illustrates the success of this approach.
- This Example sets out a comparison of the various levels of components present in human serum, human interstitial fluid and RS-I solution, as given below in Table II.
-
TABLE II Interstitial Fluid [analysed or Component Serum RS-I estimated] Sodium ions 131-148 mmoles/ L 135 mmoles/ L 136 mmoles/L Potassium ions 3.4-5.2 mmoles/L 5.0 mmoles/L 4.4 mmoles/L Calcium ions 1.12-1.46 mmoles/L 1.25 mmoles/L 1.18 mmoles/L Magnesium ions 0.38-0.72 mmoles/L 0.45 mmoles/L 0.51 mmoles/L Chloride ions 101-111 mmoles/L 119 mmoles/L 117 mmoles/L Hydrogen 21-29 mmoles/ L 25 mmoles/L 23.9 mmoles/L carbonate ions Organic acid 6.4 mmoles/ L 5 mmoles/ L 7 mmoles/L (BES) Glucose 3.6-6.1 mmoles/ L 10 mmoles/L 3.3-3.6 mmoles/L Glycerol 31-131 μmoles/ L 110 μmoles/ L 87 μmoles/L Glutamate 310-475 μmoles/ L 300 μmoles/L serum values Glutamine 188-320 μmoles/ L 400 μmoles/L serum values Aspartate 1-11 μmols/ L 20 μmols/L serum values Carnitine 35-85 μmols/ L 50 μmols/L serum values (recomb.) Choline 18-70 μmols/ L 10 μmols/L serum values Thiamine 6-135 nmols/ L 40 nmols/L serum values pyrophosphate Human insulin 6-35 mIU/ L 28 mIU/ L 24 mIU/L (recomb.) pH @ 37.4° C. 7.32-7.45 7.30-7.46 7.35-7.38 Albumin 0.65 mmoles/L NIL 0.19 mmoles/L Osmolality 264-290 265-286 264-282 (mOsm/kg water) Specific 11.7-12.3 11.9-12.6 11.8-12.2 Conductivity (mS cm−1) - The procedures consisted of a lower midline laparotomy under sterile conditions after induction of full anesthesia using an intramuscular (IM) injection of 0.1 cc Xylocaine +0.2 cc ketamine for every 100 gram body weight. Following this, the aorta of the rat is dissected and cannulated under direct vision using a 24 Gauge angiocath. This allows for direct access for large amounts of blood withdrawal as well as administration of solutions. As a maintenance dose, 0.2 cc IM injections of ketamine are given every 25 minutes to all rats. Animals are allowed to breathe spontaneously throughout the experiment and their respiratory rate is continuously monitored. A warmer is used to keep the rats at normal body temperature during experimentation. As a result of the lower midline laparotomy, the bowels become exposed to unveil the abdominal vessels. The bowels are wrapped with wet gauze (soaked in saline) to minimize water loss. At the completion of the experiment, the rat is either sacrificed while under anesthesia or the aortic perforation at the site of the catheter is repaired using 6-0 Prolene figure of 8 sutures and closure of the laparotomy incision using 2-0 Vicryl suture in 2 layers. The rats chosen for the survival part of the study are given intramuscular antibiotics and allowed ad lib feeding post-operatively. This procedure takes 25 to 30 minutes to complete per rat.
- 19 Sprague-Dawley rats of similar age (10-12 weeks) and weight (280 to 320g) were used in the experiments. The rats were randomized by random number assignment to one of 3 arms: (1) replacement of blood volume with an equal volume of physiological saline (5 rats); (2) replacement of blood volume with an equal volume of RS-I solution as defined above (7 rats); or (3) no replacement of blood losses (7 rats). The primary end point of the study here was the death of the animal documented by cardio-respiratory arrest.
- The rats were subjected to serial withdrawals of blood in 2cc increments (simulating controlled hemorrhage) every 30 minutes. At the end of each withdrawal a 0.1 ml of heparinized solution (1000 units in 20 ml of normal saline) was injected into a heparin lock to avoid blood clotting. The rats were randomly allocated to one of 3 arms as defined above.
- The data observed and collected were as follows:
-
- a. Number of blood withdrawals (hence volume of hemorrhage)
- b. Respiratory rate (measured every 10 minutes)
- c. Time span until death (survival time in minutes from onset of hemorrhage)
- d. Visible physical changes
- e. Pathology
- Survival was defined as the time from the first withdrawal of blood to the time of documentation of cardio-pulmonary arrest. Differences were considered statistically significant when the p-value was less than 0.05 (p<0.05). All values were expressed as mean ±Standard Deviation (SD). The analyses were performed using SPSS software version 13.0 (SPSS, Inc., Chicago, Ill.).
- Summary: Rats in the ‘no’ resuscitation arm had the shortest survival times and least blood volume withdrawn. Survival time and mean volume withdrawn were significantly improved by the addition of either normal saline or RS-I. RS-I provided a statistically superior survival time (p<0.01) and allowed for a larger volume of blood to be withdrawn compared to physiological saline (p<0.01).
- Survival times: The survival of rats over time as a function of the resuscitation solution used is illustrated in
FIG. 1 . Rats in the ‘no’ resuscitation arm had the shortest survival. Survival time was significantly improved by adding either saline replacement of blood losses or RS-I replacement. Both solutions showed a significant difference when compared with the survival time of non-resuscitated rats; the mean difference between RS-I and ‘no’ resuscitation groups was 89±13.13 minutes (p<0.01), and between saline and ‘no’ resuscitation was 57±15.87 minutes (p<0.05). RS-I was superior to saline and resulted in a statistically significant increase in the survival time. The mean difference in survival times between the RS-I treated rats and saline treated rats was significant at 43.40±6.90 minutes (p<0.01). - Blood volume withdrawn: The total volume of blood withdrawn for each of the study arms is set out in
FIG. 2 . Both groups of fluid resuscitated rats showed a significant difference in the volume of blood withdrawn compared to the control arm of ‘no’ resuscitation (RS-I to ‘no’ resuscitation 5.73 ±0.62 ml and saline to ‘no’ resuscitation 3.64±0.70 ml, with p<0.01 for both). The mean difference in volume of blood withdrawn from RS-I resuscitated rats in comparison to saline resuscitated rats was found to be statistically significant (p<0.01) at 2.82±0.45 ml. - Respiratory rates:
FIG. 3 illustrates the respiratory rates of rats over time in the various study arms. RS-I resuscitated rats survived the greatest time and showed a slower decline in the respiratory rate overall, though initially (first 100 minutes) a more rapid descent in respiratory rate was noted. The overall respiratory rate for saline resuscitated rats declined at a rate faster than that of RS-I infused rats and this decline was even faster still for the rats that received no fluid infusion. - RS-I appears to be a more effective plasma substitute than physiological saline with respect to survival time and volume blood loss in a rat model of controlled hemorrhagic shock.
- This study was designed as a pilot study to evaluate the safety of RS-I when administered as an intravenous (IV) infusional agent in a large animal model (swine).
- 6 pigs were used in this study arm, of both genders, ranging in weight from 27 to 35 kg. The pigs were housed in the animal care facility and were kept NPO (nothing by mouth) overnight on the night prior to the study. Each pig was housed in a separate cage.
- On
day 0, each pig was initially sedated using an intramuscular injection of ketamine (15 to 20 mg/kg) followed by induction of anesthesia and endometrial intubation. Anesthesia was maintained with halothane to achieve absence of response to surgical stimulation without depression of heart rate. Each pig received pre-operative antibiotic prophylaxis by intramuscular injection ofgentamycin 10% (1 cc/10kg). - A central venous catheter was surgically placed via direct countdown, under strict aseptic conditions, into the left internal jugular vein of each pig. The central line was extensively tunneled in the subcutaneous tissues of the pig to an exit site on the lateral and dorsal aspect of the pig neck and secured in place. This was done for two purposes; to prevent accidental catheter dislodgement and to minimize the risk of line related infections. The animals were then allowed to return to their cages to recover from the anesthetics.
- On
day 1, each pig was sedated using intramuscular injection of ketamine (35 mg/kg) and xylazine (7 mg/kg). Baseline blood samples were drawn from the central line under aseptic technique and immediately sent to the lab for analysis. The blood profile drawn was tested for complete blood counts, serum chemistry determination: electrolytes, osmolality, pH, glucose, lactate, creatinine, blood urea nitrogen (BUN) , serum enzymes (aspartate aminotransferase [SGOT/AST], alanine aminotransferase [SGPT/ALT], total creatine kinase [CK] and lactate dehydrogenase [LDH]), coagulation factors and fibrinogen levels. In addition, blood was taken for measurement of pro-inflammatory activity, e.g., neutrophil activation, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a), and the samples centrifuged and stored at −80° C. for later evaluation. - After the blood was drawn, each pig had 1.0 L of RS-I (at room temp) infused slowly over 1-2 hours via the central line. The pig was directly monitored during the infusion for any signs of ill health or unusual behaviour/manifestations. The pigs were then allowed to return to their normal living quarters and were monitored by the animal house veterinarian for any signs of ill health or unusual behavior/manifestations.
- The same procedure performed on
Day 1 was repeated onDay - RS-I the same blood profile (described below) was drawn to evaluate for any ill effects related to the RS-I administration. The pigs were then monitored for 7 days and euthanized humanely on
Day 7 by intravenous potassium chloride solution administration under sedation with ketamine. Prior to euthanasia, a final blood sample (Day 7) was collected. Blood samples were also drawn to measure TNF-α and IL-6. These samples were centrifuged at 2000 r.p.m. [20° C.] for 5 minutes and then stored at −80° C. to be later processed using commercially available porcine ELISA assays. A post-mortem examination was performed on every pig, and organs (brain, lungs, liver and kidneys) were harvested and either stored in formaldehyde or frozen at −80° C. for histological examination and apoptotic testing at a later date. - All 6 pigs were observed for 1 week, and all showed behavioural and feeding habits that were within normal limits.
- Blood results are set out in
FIG. 4 and graphically presented inFIGS. 5-9 . These blood results were within normal ranges of swine of this weight category. - No significant difference (p<0.05) was observed in serum electrolytes or osmolality over the 7-day experimental period in comparison to baseline (control') values (
FIG. 4G , Table 1;FIG. 5a-g ). Elevation of sodium ion levels to within the published range values was observed after 48 hours in Pig. Nos. 2 and 5 which returned to baseline levels by Day 7 (FIG. 5a ). Only Pig No. 6 showed a progressive elevation during the experimental period but returned, as did the overall trend level, to reside within the maximum range value of 150 mmole/L (FIG. 4G , Table 1;FIG. 5a ). - No significant change in acid-base balance (i.e., bicarbonate levels;
FIG. 5f ) or chloride levels (FIG. 4G , Table 1;FIG. 5e,f ) were observed during the same experimental periods. - While all serum metabolite baseline levels were naturally elevated on
Day 1 following the trauma of surgical manipulative procedures, all (except lactate) exhibited a trend to return to within normal serum values by Day 7 (FIG. 6 ). There was considerable variation in lactate levels with no statistically significant trend with the lactate levels below reference values (FIG. 6 ) onDay - There was the acknowledged elevation of all serum enzymes examined following the trauma of surgical manipulative procedures (
FIG. 7 ) but all (except SGPT [ALT];FIG. 7b ) showed a decline byDay 7 to acceptable serum values indicating a restoration of functional integrity of the heart, liver, lungs and kidneys. The observed elevation of SGPT [ALT] was within the 50 percentile normal serum value and not statistically different (P<0.26) within or among group data again indicating functional integrity of the heart and lungs byDay 7. - Each normovolemic pig had an estimated total blood volume of 1.8-2.3L (67 mL/kg) and each pig received a total volume of 3L of RS-I over a period of 72 hours. No hemodilution of RBC count was observed with hematocrit (Hct) values and hemoglobin (Hg) levels remaining with normal ranges up to Day 7 (
FIG. 8 a,b,c). Equally, lymphocyte count returned to baseline levels over the seven day period investigated (FIG. 8d ) with only the white blood cell (WBC) count showing a slight, insignificant elevation by Day 7 (FIG. 8e ). - In terms of the blood clotting parameters investigated, only Pig No.2 showed an anomalous baseline value for platelets which was restored to normal by Day 7 (
FIG. 9a ). The blood clotting parameters, i.e., prothrombin clotting indices (INR) and activated partial prothromboplastin times (aPTT) (seeFIG. 9b,c ) remained constant and within published limits. Fibrinogen levels did seem to show a downward trend over the seven day experimental period (FIG. 9d ) but again the values remained within acceptable limits for porcine species. - Following the infusion of RS-I over a period of 48 hours, there was an overall trend in restoration of WBC baseline levels (
FIG. 8e ) and a decrease in lymphocyte levels (FIG. 8d ) byDay 7 which suggests the absence of any pro-inflammatory effects. - It is to be acknowledged that numerous investigative studies involving swine species have noted great diversity in blood and serum profile values. In the present study, these values were consistent within the swine species examined, there being good statistical correlation.
- No hemodilution would appear to have occurred in the normovolemic pigs infused with RS-I solution during the experimental period (
FIG. 4G , Table 1). - Characteristically, volume replacement therapies are susceptible to the incidence of inflammatory, anaphylactic, hypercoagulability episodes, seemingly related to the antigenicity and/or toxicity of the various excipients used in the formulation of the blood replacement fluids administered. This does not appear to be the case in the intravenous administration of RS-I solution from the analysis of the blood cell profile data obtained.
- Of importance in this pilot study was to evaluate the safety aspects of administering RS-I solution intravenously and that there be no incidence of hyperchloremic (metabolic) acidosis, a common finding in clinical practice with volume replacement fluids. No disturbance in acid-base balance was observed in the pigs examined over a period of seven days, as evidenced by sustained bicarbonate and chloride ion levels.
- The tentative observation that suppression of the baseline serum lactate levels occurred in all the pigs studied during the infusion of RS-I solution by
Days 2 and 3 (FIG. 6b ) would appear to imply that in the RS-I infused normovolemic pig, conditions prevail to optimize: -
- a) metabolism of pyruvate (glycolysis) to maintain serum lactate levels;
- b) catabolism of tissue lactate to generate ATP and
- c) resynthesis by the liver (Cori Cycle) to form glucose or glycogen.
- All of the pigs studied showed a gradual decrease over the experimental period of serum Lactate Dehydrogenase (LDH), an enzyme intimately linked with lactate/pyruvate metabolism, and characteristically released from tissues and organs during reperfusion injury.
- Of particular interest in this study was the observation that the release of those enzymes (e.g., CPK (creatine phosphokinase), SGOT, SGPT) associated with damaged organs (e.g., heart, lung, liver, kidney) during reperfusion of intravenous solutions, while elevated initially on
Day 1 following the trauma of the surgical procedures necessitated to monitor bodily functions (see ‘Methods), gradually declined to within normal published levels (FIG. 4G , Table 1). - The above detailed study involving daily IV infusions of 1.0L of RS-I into the pig for a period of 3 days was completed successfully. It is concluded on the basis of the results obtained that RS-I possesses no apparent safety issues when administered intravenously to farm swine under clinically acceptable conditions.
- Non-heart beating donor (NHBD) pig kidneys were preserved for 2 hours under ‘cold’ (0° C. to 4° C.) static (CS) conditions in either RS-I or the commercial hypothermic preservation solutions, Soltran or UW (University of Wisconsin) or for 2 hours under ‘warm’ (31° C.) static (WS) conditions. The kidneys were subsequently reperfused with a 50:50 autologous blood/Lactated Ringer's perfusate mixture under normothermic conditions for periods of 6 to 8 hours.
- Functional parameters measured in isolated pig kidney after 6 hours of normothermic perfusion with autologous blood are set out in Table III below, where ‘n’ represents the number of kidneys tested:
-
TABLE III Functional RS-I RS-I Soltran UW parameters 4° C. 30° C. Flush Flush after 6 hours storage storage 4° C. storage 4° C. storage ‘p’ perfusion (n = 6) (n = 6) (n = 6) (n = 6) value pH 7.37 ± 0.15 7.30 ± 0.09 7.21 ± 0.1 7.23 ± 0.12 0.1468 Hydrogen carbonate 21.8 ± 6.83 17.6 ± 4.24 14.6 ± 3.08 15.3 ± 4.26 0.154 Base excess −4.7 ± 9.16 −10 ± 5.9 −9.7 ± 5.90 −13.5 ± 6.4 0.248 Serum IC levels 5.83 ± 0.34 8.01 ± 1.22 7.73 ± 1.21 8.23 ± 1.27 0.003 O2 consumption 47.3 ± 12.11 28.7 ± 6.53 31 ± 6.26 33.7 ± 15.1 0.059 ml/min/g % weight gain 12.7 ± 9 30.3 ± 9.3 21.2 ± 7.7 29.7 ± 3.44 0.0109 Total urine output 692 ± 230 257 ± 118 536 ± 221 410 ± 153 0.0103 (ml) RBF 79.3 ± 17.89 48 ± 11.28 50 ± 10.16 55.5 ± 21.9 0.0214 ml/min/100 g RVR mmHg/ml/min 0.4 ± 0.09 0.73 ± 0.26 0.52 ± 0.09 0.8 ± 0.43 0.0173 - The present study revealed that RS-I significantly outperformed other preservation solutions in maintaining renal function as assessed following kidney re-animation in autologous blood. Analyses of the data obtained over the reperfusion periods revealed that kidneys preserved in RS-I at 4° C. exhibited (1) increased oxygen consumption, (2) increased creatine clearance rates, (3) increased renal blood flow [RBF], (4) increased urine output, (5) decreased renal vascular resistance [RVR], (6) deceased weight gain (i.e. less oedema), (7) stable blood pH and retention of acid-based balance [bicarbonate ion levels], and (8) negligible loss of intracellular K+.
- Of particular significance is the observed stability of blood pH and retention of the neutral acid-base balance (H+/HCO3 −). This observed stability indicates that in RS-I preserved kidneys, the major pH buffering system, the glutamine-ammonia shuttle, had not been compromised as was observed with the other two commercially available preservation solutions (see Table III above). Of additional significance was the observation that in those kidneys preserved for 2 hours under ‘warm’ (WS) ischemic conditions in AQIX® RS-I, subsequent reperfusion over 6-8 hours resulted in a restoration of the ADP:ATP balance (see
FIG. 10 ). - The ADP:ATP ratio levels were highest in the pre-perfusion biopsies and indicative of the ischaemic damage sustained during the CS/WS storage periods (
FIG. 10 ). However, after 6 hours perfusion, the ratio had improved in both groups showing recovery of cellular function but with no significant difference (p=0.71) observed between the CS and WS groups of kidneys (MD Kay et al., 2006; Transplant International 20 (1), 88-92). - Functional viability of mammalian tissue and organ preparations was assessed following storage/perfusion of the tissues/organs for various periods in RS-I solution. Viability was assessed using a variety of functional indicators, e.g., maintenance of cell membrane potentials, neurotransmitter output, myogenicity, membrane receptor sensitivity, enzyme functions, histological changes, etc.
- Table IV below reveals the ability of RS-I solution to maintain functional viability of various mammalian animal and human tissues and organs preparations over preservation periods of varying length (between 0.3 to 10 days).
-
TABLE IV Tissue/Organ Maxm Days Preservation Conditions Species Preparations Stored ° C. Stored ° C. Experimental rat jejunum 9.0 8-12 35 jejunum 1.5 — 35 ileum 8.0 8-12 35 ileum 1.3 — 20-35 colon 5.0 — 20-35 uterus 3.0 — 35 uterus 10.0 8-12 35 detrusor muscle 2.0 — 20-35 diaphragm muscle 0.6 — 35-37 diaphragm muscle 2.0 — 20-35 soleus muscle 1.1 — 20-35 heart 0.8 — 35-37 heart 2.1 — 20-25 heart-lung 1.2 — 20-35 RBC's 4.0 No haemolysis at 4° C. kidney 1.0 — 20-35 liver 0.3 — 35 rabbit intestine (jejunum) 5.0 8-12 37 intestine (jejunum) 2.0 — 20-37 uterus 7.0 8-12 37 superior cervical 2.0 8-12 37 ganglion 0.8 — 37 RBC's 3.0 No haemolysis at 4° C. guinea pig ileum 7.0 8-12 37 detrusor muscle 4.0 8-12 37 detrusor muscle 1.0 — 20-37 heart 0.4 — 20-37 mouse soleus muscle 0.9 — 20-35 diaphragm muscle 1.5 — 20-35 intercostal muscle 0.9 — 20-35 pig kidney 0.8 0-4 37 kidney 0.8 30 37 human intercostal muscle 1.3 — 37 kidney (organ) 1.5 0-4 37 intestine(organ) 0.3 — 37 colon (biopsy) 1.3 0-4 — lung(organ) 0.3 — 37 lung bronchi (biopsy) 0.8 — 37 atrial trabeculae(biopsy) 0.6 — 37 liver(organ) 0.3 — 37 RBC's 1.3 0-4 — RBC's 0.3 — 37 Leucocytes 0.8 — 37 - To investigate the efficacy of RS-I as a resuscitation (volume expansion) solution as well as its efficacy at reducing tissue reperfusion injury following hemorrhagic trauma in the pig compared to replacement with autologous blood or Lactated Ringers (LR), a commonly used blood volume expansion solution in clinical applications.
- In this study, 23 randomly selected non-syngeneic farm pigs were used in the four experimental groups, namely, 3 ‘sham’ (control), 6 autologous blood, 6 RS-I solution and 6 LR solution. Under standardized general anesthesia conditions, the animals were instrumented to allow for full measurement of all hemodynamic profile. Pigs were then rapidly hemorrhaged from the femoral artery until the MAP reached 30 mm Hg. Hemorrhage was continued as needed to maintain the MAP at 30 +/− 2 mm Hg for 45 minutes. Shed blood was collected in ACD treated bags and the net weight used to estimate volume of hemorrhaged blood.
- At the conclusion of the 45-minute shock period, animals received either Lactated Ringer solution (LR) or RS-I solution equal to three-four times the shed blood volume, Shed whole autologous blood or no resuscitation (‘sham’ control group).
- The resuscitation fluids were given in a dynamic manner, incrementally, over a 2-hour period to maintain the MAP at 60 +/−2 mm Hg. All hemodynamic parameters were measured at baseline; at initiation of the 45- minute shock period, at 30 minutes of shock; at 45 minutes (completion) of shock; and at 30, 60, 90, and 120 minutes of resuscitation. Blood samples for blood gas analysis, lactate measurement, complete blood counts, serum chemistry determination: electrolytes, glucose, osmolarity, serum enzymes (aspartate aminotransferase [SGOT/AST], alanine aminotransferase [SGPT/ALT], total creatine kinase [CK] and lactate dehydrogenase [LDH]) and coagulation profile were drawn at the same time intervals.
- Levels of neutrophils activation were measured via myloperoxidase enzymatic method as well as TNF-alpha, IL-6 levels as indices of apoptotic (cell death) phenomena.
- After resuscitation, the animals had their cannulae removed leaving the neck venous catheter for daily blood withdrawals. During the 7 post operative days the animals were observed for any behavioral changes and underwent blood withdrawals on
post-operative days post-operative day 7 to examine for any pathological evidence of reperfusion injury in the brain, kidney, lung and liver. - All 18 pigs in the surviving three experimental groups were observed for 1 week and all showed behavioural and feeding habits that were within normal limits.
- Recovery times during the first 60 minutes of resuscitation for mean arterial (see
FIG. 11 ), central venous, pulmonary arterial occlusion pressures in the RS-I group pigs were fastest and comparable to the autologous blood group pigs but slowest in the LR group pigs. Restoration of cardiac output was significantly quicker and greater in the RS-I group pigs in comparison to both autologous blood and the LR group pigs (seeFIG. 12 ). - Serum electrolyte concentrations by
post-operative day 7 had been restored to within normal levels for all experimental groups except for elevation of the sodium ion concentration in the LR group pigs. Anion gap and Strong ion difference was within normal limits in all groups of pigs bypost-operative day 7. - Enzyme levels were elevated during
post-operative days post-operative day 7. No significant change in blood clotting parameters was observed during the seven day experimental period (see,FIG. 13 ). - On
post-operative day 7, evidence of reperfusion injury was absent in the lung and liver and insignificant in the kidney of both the RS-I and autologous blood group pigs but was a significant and prevalent feature in these three organs within the LR group pigs (seeFIG. 13 ).
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/235,634 US20210393517A1 (en) | 2007-07-03 | 2021-07-29 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0712833.3A GB0712833D0 (en) | 2007-07-03 | 2007-07-03 | Body Fluid Expander |
GB0712833.3 | 2007-07-03 | ||
PCT/GB2008/002268 WO2009004331A1 (en) | 2007-07-03 | 2008-07-03 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
US66730909A | 2009-12-30 | 2009-12-30 | |
US14/540,597 US11013684B2 (en) | 2007-07-03 | 2014-11-13 | Body fluid expanders comprising N-substituted aminosulfonic acid buffers |
US17/235,634 US20210393517A1 (en) | 2007-07-03 | 2021-07-29 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/540,597 Continuation US11013684B2 (en) | 2007-07-03 | 2014-11-13 | Body fluid expanders comprising N-substituted aminosulfonic acid buffers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210393517A1 true US20210393517A1 (en) | 2021-12-23 |
Family
ID=38421091
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/667,309 Abandoned US20100183747A1 (en) | 2007-07-03 | 2008-07-03 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
US14/540,597 Active 2029-07-19 US11013684B2 (en) | 2007-07-03 | 2014-11-13 | Body fluid expanders comprising N-substituted aminosulfonic acid buffers |
US17/235,634 Pending US20210393517A1 (en) | 2007-07-03 | 2021-07-29 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/667,309 Abandoned US20100183747A1 (en) | 2007-07-03 | 2008-07-03 | Body fluid expanders comprising n-substituted aminosulfonic acid buffers |
US14/540,597 Active 2029-07-19 US11013684B2 (en) | 2007-07-03 | 2014-11-13 | Body fluid expanders comprising N-substituted aminosulfonic acid buffers |
Country Status (8)
Country | Link |
---|---|
US (3) | US20100183747A1 (en) |
EP (1) | EP2175718B1 (en) |
JP (1) | JP5624462B2 (en) |
CN (1) | CN101795558B (en) |
ES (1) | ES2407838T3 (en) |
GB (1) | GB0712833D0 (en) |
WO (1) | WO2009004331A1 (en) |
ZA (1) | ZA201000728B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
US20080171094A1 (en) * | 2001-12-21 | 2008-07-17 | Robbert Benner | Treatment of burns |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU65921A1 (en) * | 1972-08-18 | 1974-02-21 | ||
AU3843289A (en) * | 1988-05-02 | 1989-11-29 | Cryomedical Sciences, Inc. | Blood substitute |
US5130230A (en) * | 1988-05-02 | 1992-07-14 | Cryomedical Sciences, Inc. | Blood substitute |
US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
CA2066374C (en) * | 1991-04-19 | 2002-01-29 | Paul E. Segall | Solution for perfusing primates |
AU681675B2 (en) * | 1993-06-04 | 1997-09-04 | Biotime, Inc. | Plasma-like solution |
NZ264638A (en) * | 1994-10-07 | 1997-01-29 | Maxine Helen Simmons | Aqueous buffered solution; comprises a solution with a ph from 6.8 to 7.8, containing one or more carbon sources, one or more biologically compatible salts and a zwilterionic buffer |
FR2793651B1 (en) * | 1999-05-18 | 2003-05-16 | Cair L G L | AQUEOUS TISSUE AND ORGAN CONSERVATION SOLUTION |
GB0001172D0 (en) * | 2000-01-20 | 2000-03-08 | Res Del International Limited | Physiological medium for perfusing, preserving and storing isolated cell tissue and organ samples |
CA2468113A1 (en) * | 2001-09-28 | 2003-04-03 | Harry F. Hull | A simple, fully transportable device for maintaining an excised heart in optimum condition for transplantation |
-
2007
- 2007-07-03 GB GBGB0712833.3A patent/GB0712833D0/en not_active Ceased
-
2008
- 2008-07-03 ES ES08775818T patent/ES2407838T3/en active Active
- 2008-07-03 EP EP08775818A patent/EP2175718B1/en active Active
- 2008-07-03 JP JP2010514119A patent/JP5624462B2/en active Active
- 2008-07-03 US US12/667,309 patent/US20100183747A1/en not_active Abandoned
- 2008-07-03 CN CN200880105723.0A patent/CN101795558B/en active Active
- 2008-07-03 WO PCT/GB2008/002268 patent/WO2009004331A1/en active Application Filing
-
2010
- 2010-02-01 ZA ZA2010/00728A patent/ZA201000728B/en unknown
-
2014
- 2014-11-13 US US14/540,597 patent/US11013684B2/en active Active
-
2021
- 2021-07-29 US US17/235,634 patent/US20210393517A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5405742A (en) * | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
US20080171094A1 (en) * | 2001-12-21 | 2008-07-17 | Robbert Benner | Treatment of burns |
Also Published As
Publication number | Publication date |
---|---|
CN101795558B (en) | 2014-07-16 |
ZA201000728B (en) | 2010-11-24 |
US20100183747A1 (en) | 2010-07-22 |
CN101795558A (en) | 2010-08-04 |
ES2407838T3 (en) | 2013-06-14 |
US20150139964A1 (en) | 2015-05-21 |
US11013684B2 (en) | 2021-05-25 |
EP2175718A1 (en) | 2010-04-21 |
JP5624462B2 (en) | 2014-11-12 |
EP2175718B1 (en) | 2013-02-20 |
JP2010531866A (en) | 2010-09-30 |
GB0712833D0 (en) | 2007-08-08 |
WO2009004331A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005302851B2 (en) | Composition for cold preservation and perfusion of organs | |
AU680928B2 (en) | Solutions for tissue preservation and bloodless surgery and methods using same | |
RU2019965C1 (en) | Composition for preservation and storage of organ to be implanted in patient | |
JP5180912B2 (en) | Methods and compositions for use in perfusion applications | |
US6946241B2 (en) | Physiological medium for perfusing, preserving and storing isolated cell, tissue and organ samples | |
US10300029B2 (en) | Organ protection solutions and method of use | |
US5407428A (en) | Solutions for use as plasma expanders and substitutes | |
US6627393B2 (en) | Solutions for use as plasma expanders and substitutes | |
US20210393517A1 (en) | Body fluid expanders comprising n-substituted aminosulfonic acid buffers | |
US20230284612A1 (en) | Organ preservation and/or perfusion solution | |
US11213026B2 (en) | Solution for preserving and/or rinsing an organ to be transplanted | |
JPH0822801B2 (en) | Solution for organ preservation | |
KR100304594B1 (en) | Composition for the Preservation of Organs and Blood Cells | |
CA2747680A1 (en) | Solutions for volume therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AQIX LTD, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REES, DOUGLAS;REEL/FRAME:056484/0802 Effective date: 20091230 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |